<SEC-DOCUMENT>0001193125-23-019198.txt : 20230130
<SEC-HEADER>0001193125-23-019198.hdr.sgml : 20230130
<ACCEPTANCE-DATETIME>20230130171034
ACCESSION NUMBER:		0001193125-23-019198
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		19
CONFORMED PERIOD OF REPORT:	20230126
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230130
DATE AS OF CHANGE:		20230130

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Village Farms International, Inc.
		CENTRAL INDEX KEY:			0001584549
		STANDARD INDUSTRIAL CLASSIFICATION:	AGRICULTURE PRODUCTION - CROPS [0100]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			Z4
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38783
		FILM NUMBER:		23569014

	BUSINESS ADDRESS:	
		STREET 1:		4700 - 80TH STREET
		CITY:			DELTA, BRITISH COLUMBIA
		STATE:			Z4
		ZIP:			V4K 3N3
		BUSINESS PHONE:		732-676-3008

	MAIL ADDRESS:	
		STREET 1:		4700 - 80TH STREET
		CITY:			DELTA, BRITISH COLUMBIA
		STATE:			Z4
		ZIP:			V4K 3N3
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d369529d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:vff="http://villagefarms.com/20230126" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>Form 8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_AmendmentFlag_duration_2023-01-26_to_2023-01-26" name="dei:AmendmentFlag" contextRef="duration_2023-01-26_to_2023-01-26">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey_duration_2023-01-26_to_2023-01-26" name="dei:EntityCentralIndexKey" contextRef="duration_2023-01-26_to_2023-01-26">0001584549</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="vff-20230126.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2023-01-26_to_2023-01-26"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001584549</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-26</xbrli:startDate> <xbrli:endDate>2023-01-26</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2023-01-26_to_2023-01-26">8-K</ix:nonNumeric></span></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2023-01-26_to_2023-01-26" format="ixt:date-monthname-day-year-en">January 26, 2023</ix:nonNumeric></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2023-01-26_to_2023-01-26">VILLAGE FARMS INTERNATIONAL, INC.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2023-01-26_to_2023-01-26" format="ixt-sec:edgarprovcountryen">Ontario</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2023-01-26_to_2023-01-26">001-38783</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2023-01-26_to_2023-01-26">98-1007671</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or Other Jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of Incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File No.)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employee</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr> </table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2023-01-26_to_2023-01-26">4700-80th Street</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2023-01-26_to_2023-01-26">Delta</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2023-01-26_to_2023-01-26" format="ixt-sec:stateprovnameen">British Columbia</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressCountry" contextRef="duration_2023-01-26_to_2023-01-26" format="ixt-sec:countrynameen">Canada</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of Principal Executive Offices)</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2023-01-26_to_2023-01-26">V4K&#160;3N3</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(zip code)</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2023-01-26_to_2023-01-26">604</ix:nonNumeric>) <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2023-01-26_to_2023-01-26">940-6012</ix:nonNumeric></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code)</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2023-01-26_to_2023-01-26" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr> </table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2023-01-26_to_2023-01-26" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr> </table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2023-01-26_to_2023-01-26" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr> </table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2023-01-26_to_2023-01-26" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr> </table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of Each Class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of Each Exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on Which Registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2023-01-26_to_2023-01-26">Common Shares, without par value</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2023-01-26_to_2023-01-26">VFF</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2023-01-26_to_2023-01-26" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></td></tr> </table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">Emerging growth company&#160;&#160;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2023-01-26_to_2023-01-26" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div> <p style="page-break-before:always"></p> <hr style="color:#999999;height:3px;width:100%" /> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top"><span style="font-weight:bold">Item&#160;1.01.</span></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement.</p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January 26, 2023, Village Farms International, Inc. (the &#8220;<span style="text-decoration:underline">Company</span>&#8221;) entered into securities purchase agreements (the &#8220;<span style="text-decoration:underline">Securities Purchase Agreements</span>&#8221;) for the purchase and sale of 18,350,000 of its common shares, no par value per share (&#8220;<span style="text-decoration:underline">Common Shares</span>&#8221;), at US$1.35 per share together with accompanying warrants to purchase up to 18,350,000 Common Shares, which have an exercise price of US$1.65 per share (the &#8220;<span style="text-decoration:underline">Warrants</span>&#8221;), pursuant to a registered direct offering (the &#8220;<span style="text-decoration:underline">Offering</span>&#8221;). The Offering was made pursuant to the Company&#8217;s existing shelf registration statement on Form <span style="white-space:nowrap">S-3</span> (File <span style="white-space:nowrap">No.&#160;333-257857),</span> which was filed with the Securities and Exchange Commission (the &#8220;<span style="text-decoration:underline">Commission</span>&#8221;) on July 12, 2021 and amended on June&#160;9, 2022 and declared effective by the Commission on June&#160;21, 2022.</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January 30, 2023, the Company closed the Offering. The gross proceeds from the offering will be<span style="font-weight:bold">&#160;</span>approximately US$25 million before deducting placement agent fees and other offering expenses payable by the Company. The proceeds from the Offering are intended to be used for general working capital. The accompanying Warrants have an exercise price of US$1.65 and will be exercisable beginning six months from issuance and will expire five years from the date of initial exercisability. Proceeds from the exercise of all the warrants would be approximately US$30 million over this period.</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The representations, warranties and covenants contained in each Securities Purchase Agreement were made solely for the benefit of the parties to the Securities Purchase Agreements. In addition, such representations, warranties and covenants (i)&#160;are intended as a way of allocating the risk between the parties to the Securities Purchase Agreements and not as statements of fact, and (ii)&#160;may apply standards of materiality in a way that is different from what may be viewed as material by shareholders of, or other investors in, the Company. Accordingly, a form of Securities Purchase Agreement is filed with this report only to provide investors with information regarding the terms of transaction, and not to provide investors with any other factual information regarding the Company. Shareholders should not rely on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or condition of the Company. Moreover, information concerning the subject matter of the representations and warranties may change after the date of the Securities Purchase Agreements, which subsequent information may or may not be fully reflected in the Company&#8217;s public disclosures.</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A.G.P./Alliance Global Partners and Cantor Fitzgerald&#160;&amp; Co. acted as <span style="white-space:nowrap">co-lead</span> placement agents (collectively, the &#8220;<span style="text-decoration:underline">Placement Agents</span>&#8221;) for the Offering pursuant to a Placement Agent Agreement, dated January 26, 2023 (the &#8220;<span style="text-decoration:underline">Placement Agent Agreement</span>&#8221;). Under the Placement Agent Agreement, the Placement Agents each agreed to use commercially reasonable &#8220;best efforts&#8221; to arrange for the sale of the Common Shares and the Warrants, and the Company agreed to pay the Placement Agents a cash fee equal to 5.5% of the gross proceeds of the Offering. The Placement Agent Agreement contains customary representations, warranties and indemnification by the Company. In addition, in connection with the Offering, the directors and executive officers of the Company entered into <span style="white-space:nowrap">lock-up</span> agreements with the Placement Agents (the &#8220;<span style="text-decoration:underline">Lock-Up Agreements</span>&#8221;), which each provide for a <span style="white-space:nowrap">90-day</span> lockup period, subject to customary exceptions.</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing descriptions of the Placement Agent Agreement, the Securities Purchase Agreements, the Warrants and the <span style="white-space:nowrap">Lock-Up</span> Agreements do not purport to be complete and are qualified in their entirety by reference to the full text of the Placement Agent Agreement, the form of Warrant, the form of Securities Purchase Agreement and the form of <span style="white-space:nowrap">Lock-Up</span> Agreement, which are filed as Exhibits 1.1, 4.1, 10.1 and 10.2, respectively, to this Current Report on Form <span style="white-space:nowrap">8-K</span> and are incorporated by reference herein.</p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top"><span style="font-weight:bold">Item&#160;7.01</span></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Regulation FD Disclosure</p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January 30, 2023, the Company issued a press release announcing that it has closed the Offering. A copy of the press release is attached as Exhibit 99.1 of this Current Report on Form <span style="white-space:nowrap">8-K</span> and incorporated into this Item 7.01 by reference.</p></div></div> <p style="page-break-before:always"></p> <hr style="color:#999999;height:3px;width:100%" /> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information contained in this Current Report on Form <span style="white-space:nowrap">8-K</span> under Item 7.01, including Exhibit 99.1, is being furnished pursuant to Item 7.01 of Form <span style="white-space:nowrap">8-K</span> and shall not be deemed to be &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;<span style="text-decoration:underline">Exchange Act</span>&#8221;), or otherwise subject to the liabilities of that section. The information contained in this Current Report on Form <span style="white-space:nowrap">8-K</span> under Item 7.01, including Exhibit&#160;99.1, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.</p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top"><span style="font-weight:bold">Item&#160;9.01</span></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits.</p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(d) Exhibits.</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td style="width:93%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Exhibit</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Title</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;1.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d369529dex11.htm">Placement Agent Agreement, dated January 26, 2023, among Village Farms International, Inc., A.G.P./Alliance Global Partners and Cantor Fitzgerald&#160;&amp; Co. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;4.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d369529dex41.htm">Form of Warrant </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;5.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d369529dex51.htm">Opinion of Torys LLP, dated January 30, 2023 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d369529dex101.htm">Form of Securities Purchase Agreement </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d369529dex102.htm">Form of <span style="white-space:nowrap">Lock-Up</span> Agreement </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d369529dex51.htm">Consent of Torys LLP (contained in Exhibit 5.1 above) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d369529dex991.htm">Closing Press Release dated January&#160;30, 2023 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr></table></div></div> <p style="page-break-before:always"></p> <hr style="color:#999999;height:3px;width:100%" /> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: January 30, 2023</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">
<tr>
<td style="width:12%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:87%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">VILLAGE FARMS INTERNATIONAL, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Stephen C. Ruffini</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Stephen C. Ruffini</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Executive Vice President and Chief Financial Officer</td></tr></table></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d369529dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PLACEMENT AGENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">January&nbsp;26, 2023 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Village Farms
International, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4700-80th Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Delta, British
Columbia </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Canada, V4K 3N3 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Mr.&nbsp;DeGiglio: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This letter (the &#147;<B>Agreement</B>&#148;) constitutes the agreement between A.G.P./Alliance Global Partners (&#147;<B>AGP</B>&#148;) as <FONT
STYLE="white-space:nowrap">co-lead</FONT> placement agent, and Cantor Fitzgerald&nbsp;&amp; Co. (&#147;<B>Cantor</B>&#148;) as <FONT STYLE="white-space:nowrap">co-lead</FONT> placement agent (each of AGP and Cantor a &#147;<B>Placement</B>
<B>Agent</B>&#148; and collectively the &#147;<B>Placement Agents</B>&#148;) and Village Farms International, Inc., a corporation continued under the laws of the Province of Ontario (the &#147;<B>Company</B>&#148;), that the Placement Agents shall
serve as the exclusive <FONT STYLE="white-space:nowrap">co-placement</FONT> agents for the Company, on a &#147;reasonable best efforts&#148; basis, in connection with the proposed placement (the &#147;<B>Placement</B>&#148;) of the Company&#146;s
Common Shares, no par value (the &#147;<B>Common Shares</B>&#148; and the Common Shares to be sold pursuant to the Placement, the &#147;<B>Shares</B>&#148;) and warrants to purchase Common Shares (the &#147;<B>Warrants</B>&#148; and together and the
Shares, the &#147;<B>Securities</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Securities actually placed by the Placement Agents are referred to herein as the &#147;<B>Placement
Agent</B> <B>Securities</B>&#148;. The terms of the Placement shall be mutually agreed upon by the Company and the purchasers (each, a &#147;<B>Purchaser</B>&#148; and collectively, the &#147;<B>Purchasers</B>&#148;), and nothing herein constitutes
that the Placement Agents would have the power or authority to bind the Company or any Purchaser, or an obligation for the Company will issue any Securities or complete the Placement. The Company expressly acknowledges and agrees that the Placement
Agents&#146; obligations hereunder are on a reasonable best efforts basis only and that the execution of this Agreement does not constitute a commitment by the Placement Agents to purchase the Securities and does not ensure the successful placement
of the Securities or any portion thereof or the success of the Placement Agents with respect to securing any other financing on behalf of the Company. The Placement Agents may retain other brokers or dealers to act as
<FONT STYLE="white-space:nowrap">sub-agents</FONT> or selected-dealers on its behalf in connection with the Placement. Certain affiliates of the Placement Agents may participate in the Placement by purchasing some of the Placement Agent Securities.
The sale of Placement Agent Securities to any Purchaser will be evidenced by a securities purchase agreement (each, a &#147;<B>Purchase Agreement</B>&#148; and collectively, the &#147;<B>Purchase</B> <B>Agreements</B>&#148;) between the Company and
such Purchaser, in a form reasonably acceptable to the Company and the Purchaser. Capitalized terms that are not otherwise defined herein have the meanings given to such terms in the Purchase Agreements. Prior to the signing of any Purchase
Agreement, officers of the Company will be available to answer inquiries from prospective Purchasers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>SECTION 1.</U> <U>REPRESENTATIONS AND WARRANTIES
OF THE COMPANY; COVENANTS OF THE COMPANY</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A. <U>Representations of the Company</U>. With respect to the Placement Agents and the Securities, each of
the representations and warranties (together with any related disclosure schedules thereto) and covenants made by the Company to the Purchasers in the Purchase Agreements in connection with the Placement, is hereby incorporated herein by reference
into this Agreement (as though fully restated herein) and is, as of the date of this Agreement and as of the Closing Date, hereby made to, and in favor of, the Placement Agents. In addition to the foregoing, the Company represents and warrants that
from the period commencing one hundred eighty days prior to the date of this Agreement, except as otherwise disclosed to the Placement Agents there have been no affiliations with any member firm of the Financial Industry Regulatory Authority, Inc.
(&#147;<B>FINRA</B>&#148;) among the Company&#146;s officers, directors or, to the knowledge of the Company, any five percent (5.0%) or greater securityholder of the Company, except as set forth in the Purchase Agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">B. <U>Covenants of the Company</U>. The Company covenants and agrees to continue to retain (i)&nbsp;a firm of independent PCAOB registered public accountants
for a period of at least five (5)&nbsp;years after the Closing Date and (ii)&nbsp;a competent transfer agent with respect to the Common Shares for a period of five (5)&nbsp;years after the Closing Date. In addition, from the date hereof until 90
days after the Closing Date, neither the Company nor any Subsidiary shall issue, enter into any agreement to issue or announce the issuance or proposed issuance of Common Shares or Common Share Equivalents, except that such restriction shall not
apply with respect to an Exempt Issuance. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>SECTION 2</U>. <U>REPRESENTATIONS OF THE PLACEMENT AGENTS</U>. Each Placement Agent represents and
warrants that it (i)&nbsp;is a member in good standing of FINRA, (ii)&nbsp;is registered as a broker/dealer under the Exchange Act, (iii)&nbsp;is licensed as a broker/dealer under the laws of the United States of America, applicable to the offers
and sales of the Placement Agent Securities by the Placement Agent, (iv)&nbsp;is and will be a corporate body validly existing under the laws of its place of incorporation, (v)&nbsp;has full power and authority to enter into and perform its
obligations under this Agreement. Each Placement Agent will immediately notify the Company in writing of any change in its status with respect to subsections (i)&nbsp;through (v)&nbsp;above. Each Placement Agent covenants that it will use its
reasonable best efforts to conduct the Placement hereunder in compliance with the provisions of this Agreement and the requirements of applicable law. The Placement Agents will not solicit or sell any of the Placement Agent Securities to persons
resident or domiciled in Canada. Each Placement Agent further covenants that it will provide the Company with any information that it reasonably requires to fulfill any securities law filings in Canada or the United States, including in respect of
Purchaser information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>SECTION 3</U>. <U>COMPENSATION</U>. In consideration of the services to be provided for hereunder, the Company shall pay to AGP
or its respective designees a cash fee of 2.75% of the aggregate gross proceeds raised from the sale of the Placement Agent Securities and shall pay to Cantor or its respective designees a cash fee of 2.75% of the aggregate gross proceeds raised
from the sale of the Placement Agent Securities (collectively, the &#147;<B>Cash Fee</B>&#148;). The Cash Fee shall be paid on the Closing Date. The Company shall not be required to pay the Placement Agents any fees or expenses except for the Cash
Fee. The Placement Agents reserve the right to reduce any item of compensation or adjust the terms thereof as specified herein in the event that a determination shall be made by FINRA to the effect that the Placement Agents&#146; aggregate
compensation is in excess of FINRA Rules or that the terms thereof require adjustment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>SECTION 4</U>. <U>EXPENSES</U>. The Company agrees to pay all
costs, fees and expenses incurred by the Company in connection with the performance of its obligations hereunder and in connection with the transactions contemplated hereby, including, without limitation: (i)&nbsp;all expenses incident to the
issuance, delivery and qualification of the Placement Agent Securities (including all printing and engraving costs); (ii) all fees and expenses of the Company&#146;s transfer agent; (iii)&nbsp;all necessary issue, transfer and other stamp taxes in
connection with the issuance and sale of the Placement Agent Securities; (iv)&nbsp;all fees and expenses of the Company&#146;s counsel, independent public or certified public accountants and other advisors; (v)&nbsp;all costs and expenses incurred
in connection with the preparation, printing, filing, shipping and distribution of the Registration Statement (including financial statements, exhibits, schedules, consents and certificates of experts) and the Prospectus, and all amendments and
supplements thereto, and this Agreement; (vi)&nbsp;all filing fees, reasonable attorneys&#146; fees and expenses incurred by the Company in connection with qualifying or registering (or obtaining exemptions from the qualification or registration of)
all or any part of the Placement Agent Securities for offer and sale under the state securities or blue sky laws or the securities laws of any other country; (vii)&nbsp;the fees and expenses associated with including the Shares on the Trading
Market; and (viii)&nbsp;up to $75,000 for reasonable and accountable expenses related to legal fees of counsel to the Placement Agents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>SECTION 5</U>.
<U>INDEMNIFICATION</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A. To the extent permitted by law, with respect to the Placement Agent Securities, the Company will indemnify the Placement
Agents and their affiliates, directors, officers, employees, members and controlling persons (within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act) against all losses, claims, damages, expenses and
liabilities, as the same are incurred (including the reasonable fees and expenses of counsel), relating to or arising out of its activities hereunder or pursuant to this Agreement, except to the extent that any losses, claims, damages, expenses or
liabilities (or actions in respect thereof) are found in a final judgment (not subject to appeal) by a court of law to have resulted primarily and directly from the Placement Agents&#146; willful misconduct or gross negligence in performing the
services described herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">B. Promptly after receipt by the Placement Agents of notice of any claim or the commencement of any action or proceeding with
respect to which the Placement Agents are entitled to indemnity hereunder, the Placement Agents will notify the Company in writing of such claim or of the commencement of such action or proceeding, but failure to so notify the Company shall not
relieve the Company from any obligation it may have hereunder, except and only </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to the extent such failure results in the forfeiture by the Company of substantial rights and defenses. If the Company so elects or is requested by the Placement Agents, the Company will assume
the defense of such action or proceeding and will employ counsel reasonably satisfactory to the Placement Agents and will pay the fees and expenses of such counsel. Notwithstanding the preceding sentence, the Placement Agents will be entitled to
employ counsel separate from counsel for the Company and from any other party in such action if counsel for the Placement Agents reasonably determines that it would be inappropriate under the applicable rules of professional responsibility for the
same counsel to represent both the Company and the Placement Agents. In such event, the reasonable fees and disbursements of no more than one such separate counsel will be paid by the Company, in addition to fees of local counsel. The Company will
have the right to settle the claim or proceeding provided that the Company will not settle any such claim, action or proceeding without the prior written consent of the Placement Agents, which will not be unreasonably withheld. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">C. The Company agrees to notify the Placement Agents promptly of the assertion against it or any other person of any claim or the commencement of any action
or proceeding relating to a transaction contemplated by this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">D. If for any reason the foregoing indemnity is unavailable to the Placement
Agents or insufficient to hold the Placement Agents harmless, then the Company shall contribute to the amount paid or payable by the Placement Agents as a result of such losses, claims, damages or liabilities in such proportion as is appropriate to
reflect not only the relative benefits received by the Company on the one hand and the Placement Agents on the other, but also the relative fault of the Company on the one hand and the Placement Agents on the other that resulted in such losses,
claims, damages or liabilities, as well as any relevant equitable considerations. The amounts paid or payable by a party in respect of losses, claims, damages and liabilities referred to above shall be deemed to include any legal or other fees and
expenses incurred in defending any litigation, proceeding or other action or claim. Notwithstanding the provisions hereof, each Placement Agent&#146;s share of the liability hereunder shall not be in excess of the amount of fees actually received,
or to be received, by each Placement Agent under this Agreement (excluding any amounts received as reimbursement of expenses incurred by each Placement Agent). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">E. These indemnification provisions shall remain in full force and effect whether or not the transaction contemplated by this Agreement is completed and shall
survive the termination of this Agreement, and shall be in addition to any liability that the Company might otherwise have to any indemnified party under this Agreement or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>SECTION 6</U>. <U>ENGAGEMENT TERM</U>. The Placement Agents&#146; engagement hereunder will be until the earlier of (i)&nbsp;January 31, 2023 and
(ii)&nbsp;the Closing Date. The date of termination of this Agreement is referred to herein as the &#147;<B>Termination Date</B>.&#148; The Company may elect to terminate the engagement hereunder for any reason prior to the Termination Date but will
remain responsible for fees and expenses pursuant to Section&nbsp;3 hereof and fees with respect to the Placement Agent Securities if sold in the Placement. Notwithstanding anything to the contrary contained herein, the provisions concerning the
Company&#146;s obligation to pay any fees actually earned pursuant to Section&nbsp;3 hereof, to pay expenses actually incurred pursuant to Section&nbsp;3 hereof, and the provisions concerning confidentiality, indemnification and contribution
contained herein will survive any expiration or termination of this Agreement. If this Agreement is terminated prior to the completion of the Placement, all fees and expenses due to the Placement Agents shall be paid by the Company to the Placement
Agents as soon as practicable after the Termination Date (in the event such fees are earned or owed as of the Termination Date). Each Placement Agent agrees not to use any confidential information concerning the Company provided to such Placement
Agent by the Company for any purposes other than those contemplated under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>SECTION 7</U>. <U>PLACEMENT AGENT INFORMATION</U>. The
Company agrees that any information or advice rendered by each Placement Agent in connection with this engagement is for the confidential use of the Company only in their evaluation of the Placement and, except as otherwise required by law, the
Company will not disclose or otherwise refer to the advice or information in any manner without each Placement Agent&#146;s prior written consent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>SECTION 8</U>. <U>NO FIDUCIARY RELATIONSHIP</U>. This Agreement does not create, and shall not be construed as creating rights enforceable by any person or
entity not a party hereto, except those entitled hereto by virtue of the indemnification provisions hereof. The Company acknowledges and agrees that each Placement Agent is not and shall not be construed as a fiduciary of the Company and shall have
no duties or liabilities to the equity holders or the creditors of the Company or any other person by virtue of this Agreement or the retention of the Placement Agents hereunder, all of which are hereby expressly waived. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>SECTION 9</U>. <U>CONDITIONS OF THE OBLIGATIONS OF THE PLACEMENT AGENTS</U>. The obligations of the
Placement Agents, and the closing of the sale of the Placement Agent Securities hereunder are subject to the accuracy, when made and on the Closing Date, of the representations and warranties on the part of the Company contained herein and in the
Purchase Agreement, to the performance by the Company of its obligations hereunder and in the Purchase Agreement, and to each of the following additional terms and conditions, except as otherwise disclosed to and acknowledged and waived by the
Placement Agents: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A. All corporate proceedings and other legal matters incident to the authorization, form, execution, delivery and validity of each of
this Agreement, the Placement Agent Securities, and all other legal matters relating to this Agreement and the transactions contemplated hereby with respect to the Placement Agent Securities shall be reasonably satisfactory in all material respects
to the Placement Agents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">B. The Placement Agents shall have received from outside U.S. counsel to the Company such counsel&#146;s written opinion with
respect to the Placement Agent Securities, and a written statement providing certain <FONT STYLE="white-space:nowrap">&#147;10b-5&#148;</FONT> negative assurances in respect of the Registration Statement and the Prospectus Supplement, each addressed
to the Placement Agents and dated as of the Closing Date, in form and substance reasonably satisfactory to the Placement Agents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">C. The Placement Agents
shall have received customary certificates of the Company&#146;s executive officers, as to the accuracy of the representations and warranties contains in the Purchase Agreement, and a certificate of the Company&#146;s secretary certifying
(i)&nbsp;that the Company&#146;s charter documents are true and complete, have not been modified and are in full force and effect; (ii)&nbsp;that the resolutions of the Company&#146;s Board of Directors relating to the Placement are in full force
and effect and have not been modified; and (iii)&nbsp;as to the incumbency of the officers of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">D. The Common Shares shall be registered under
the Exchange Act and, as of the Closing Date, the Company shall have received approval to list or quote all Shares sold in the offering on the Trading Markets for which such approvals are required. The Company shall have taken no action designed to,
or likely to have the effect of terminating the registration of the Common Shares under the Exchange Act or delisting or suspending from trading the Common Shares from the applicable Trading Markets, nor has the Company received any information
suggesting that the Commission or the applicable Trading Markets are contemplating terminating such registration or listings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">E. No action shall have
been taken and no statute, rule, regulation or order shall have been enacted, adopted or issued by any governmental agency or body which would, as of the Closing Date, prevent the issuance or sale of the Placement Agent Securities or materially and
adversely affect or potentially and adversely affect the business or operations of the Company; and no injunction, restraining order or order of any other nature by any federal or state court of competent jurisdiction shall have been issued as of
the Closing Date which would prevent the issuance or sale of the Placement Agent Securities or materially and adversely affect or potentially and adversely affect the business or operations of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">F. The Company shall have entered into a Purchase Agreement with each of the Purchasers of the Placement Agent Securities and such agreements shall be in full
force and effect and shall contain representations, warranties and covenants of the Company as agreed upon between the Company and the Purchasers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any
of the conditions specified in this Section&nbsp;8 shall not have been fulfilled when and as required by this Agreement, all obligations of the Placement Agents hereunder may be cancelled by the Placement Agents at, or at any time prior to, the
Closing Date. Notice of such cancellation shall be given to the Company in writing or orally. Any such oral notice shall be confirmed promptly thereafter in writing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>SECTION 10</U>. <U>GOVERNING LAW</U>. This Agreement will be governed by, and construed in accordance with, the laws of the State of New York applicable to
agreements made and to be performed entirely in such State. This Agreement may not be assigned by either party without the prior written consent of the other party. This Agreement shall be binding upon and inure to the benefit of the parties hereto,
and their respective successors and permitted assigns. Any right to trial by jury with respect to any dispute arising under this Agreement or any transaction or conduct in connection herewith is waived. Any dispute arising under this Agreement may
be brought into the courts of the State of New York or into the Federal Court located in New York, New York and, by execution and delivery of this Agreement, the Company hereby accepts for itself and in respect of its property, generally and
unconditionally, the jurisdiction of aforesaid courts. Each party hereto hereby irrevocably waives personal service of </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
process and consents to process being served in any such suit, action or proceeding by delivering a copy thereof via overnight delivery (with evidence of delivery) to such party at the address in
effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any
manner permitted by law. If either party shall commence an action or proceeding to enforce any provisions of this Agreement, then the prevailing party in such action or proceeding shall be reimbursed by the other party for its attorney&#146;s fees
and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>SECTION 11</U>. <U>ENTIRE
AGREEMENT/MISCELLANEOUS</U>. This Agreement embodies the entire agreement and understanding between the parties hereto, and supersedes all prior agreements and understandings, relating to the subject matter hereof. If any provision of this Agreement
is determined to be invalid or unenforceable in any respect, such determination will not affect such provision in any other respect or any other provision of this Agreement, which will remain in full force and effect. This Agreement may not be
amended or otherwise modified or waived except by an instrument in writing signed by both the Placement Agents and the Company. The representations, warranties, agreements and covenants contained herein shall survive the Closing Date of the
Placement and delivery of the Placement Agent Securities. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have
been signed by each party and delivered to the other party, it being understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or a .pdf format file, such signature shall
create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or .pdf signature page were an original thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>SECTION 12</U>. <U>NOTICES</U>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in
writing and shall be deemed given and effective on the earliest of (a)&nbsp;the date of transmission, if such notice or communication is sent to the email address specified on the signature pages attached hereto prior to 6:30 p.m. (New York City
time) on a business day, (b)&nbsp;the next business day after the date of transmission, if such notice or communication is sent to the email address on the signature pages attached hereto on a day that is not a business day or later than 6:30 p.m.
(New York City time) on any business day, (c)&nbsp;the third business day following the date of mailing, if sent by U.S. internationally recognized air courier service, or (d)&nbsp;upon actual receipt by the party to whom such notice is required to
be given. The address for such notices and communications shall be as set forth on the signature pages hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>SECTION 13</U>. <U>PRESS
ANNOUNCEMENTS</U>. The Company agrees that the Placement Agents shall, on and after the Closing Date, have the right to reference the Placement and each Placement Agent&#146;s role in connection therewith in such Placement Agent&#146;s marketing
materials and on its website and to place advertisements in financial and other newspapers and journals, in each case at its own expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>The remainder of this page has been intentionally left blank.</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please confirm that the foregoing correctly sets forth our agreement by signing and returning to the
Placement Agents the enclosed copy of this Agreement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>A.G.P./ALLIANCE GLOBAL PARTNERS</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Thomas T. Higgins</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Thomas T. Higgins</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Managing Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><U>Address for notice:</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">590 Madison Avenue 28th Floor</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New
York 10022</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Thomas Higgins</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Email:
thiggins@allianceg.com</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CANTOR FITZGERALD&nbsp;&amp; CO</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Sage Kelly</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Sage Kelly</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Senior Managing Director and Head of Investment Banking</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><U>Address for notice:</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">110 East 59th Street</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10022</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Email:</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Company signature page follows] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accepted and Agreed to as of the date first written above: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="78%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="5"><B>VILLAGE FARMS INTERNATIONAL, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Stephen C. Ruffini</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Stephen C. Ruffini</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Executive Vice President and Chief Financial Officer</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Address for notice</U>: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4700-80th Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Delta, British Columbia </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Canada, V4K 3N3 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>d369529dex41.htm
<DESCRIPTION>EX-4.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF COMMON SHARE PURCHASE WARRANT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VILLAGE FARMS INTERNATIONAL, INC. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Warrant Shares: _______</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Initial Exercise Date: July [__], 2023</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Issue Date: January [__], 2023</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS COMMON SHARE PURCHASE WARRANT (the &#147;<U>Warrant</U>&#148;) certifies that, for value received,
[_________________] or its assigns (the &#147;<U>Holder</U>&#148;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after July [__], 2023 (the &#147;<U>Initial
Exercise Date</U>&#148;) and on or prior to 5:00 p.m. (New York City time) on July [__], 2028 (the &#147;<U>Termination Date</U>&#148;), but not thereafter, to subscribe for and purchase from Village Farms International, Inc., a corporation
continued under the laws of the Province of Ontario (the &#147;<U>Company</U>&#148;), up to [______] common shares, without par value (the &#147;Common Shares&#148;) (as subject to adjustment hereunder, the &#147;<U>Warrant Shares</U>&#148;). This
Warrant is one of the Common Share Purchase Warrants (the &#147;<U>Warrants</U>&#148;) issued pursuant to (i)&nbsp;that certain Securities Purchase Agreement, dated as of January [__], 2023 (the &#147;<U>Subscription Date</U>&#148;) by and between
the Company and investors party thereto, (ii)&nbsp;the Company&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File number <FONT STYLE="white-space:nowrap">333-257857)</FONT> (the &#147;<U>Registration
Statement</U>&#148;) and (iii)&nbsp;the Company&#146;s prospectus supplement, dated as of January [__], 2023, and the related base prospectus, included in the Registration Statement (collectively, the &#147;<U>Prospectus</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purchase price of one Common Share under this Warrant shall be equal to the Exercise Price, as defined in Section&nbsp;2(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section<U></U>&nbsp;1. <U>Definitions</U>. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain
Securities Purchase Agreement (the &#147;<U>Purchase Agreement</U>&#148;), dated January&nbsp;26, 2023, among the Company and the Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section<U></U>
2. <U>Exercise</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <U>Exercise of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or
in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile copy (or.pdf copy via <FONT STYLE="white-space:nowrap">e-mail</FONT> attachment) of the
Notice of Exercise in the form annexed hereto (the &#147;<U>Notice of Exercise</U>&#148;). Within the earlier of (i)&nbsp;two (2) Trading Days and (ii)&nbsp;the number of Trading Days comprising the Standard Settlement Period (as defined in
Section&nbsp;2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the unpaid portion of the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or
cashier&#146;s check drawn on a United States bank unless the cashless exercise procedure specified in Section&nbsp;2(c) below is specified in the applicable Notice of Exercise. No <FONT STYLE="white-space:nowrap">ink-original</FONT> Notice of
Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically
surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation
within three (3)&nbsp;Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall
have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant
Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1)&nbsp;Trading Day of receipt of such notice.<B> The Holder and any assignee, by acceptance of this Warrant, acknowledge
and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on
the face hereof.</B> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <U>Exercise Price</U>. The exercise price per Common Share under this Warrant shall be
$1.65, subject to adjustment hereunder (the &#147;<U>Exercise Price</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) <U>Cashless Exercise</U>. If at any time during the
term of this Warrant, there is no effective registration statement (which may be the Registration Statement) registering, or no current prospectus available for, the issuance or resale of the Warrant Shares by the Holder, in whole or in part, at
such time by means of a &#147;cashless exercise&#148; in which the Holder shall be entitled to receive a number of Warrant Shares determined according to the following formula (a &#147;<U>Cashless Exercise</U>&#148;): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Net Number = <U>(A x B) - (A x C)</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">B </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For purposes of the foregoing
formula: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(A) = the total number of shares with respect to which the Warrants are then being exercised. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(B) = as applicable: (i)&nbsp;the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of
Exercise is (1)&nbsp;both executed and delivered pursuant to Section&nbsp;2(a) hereof on a day that is not a Trading Day or (2)&nbsp;both executed and delivered pursuant to Section&nbsp;2(a) hereof on a Trading Day prior to the opening of
&#147;regular trading hours&#148; (as defined in Rule 600(b)(64) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii)&nbsp;at the option of the Holder, either (y)&nbsp;the VWAP on the Trading Day immediately
preceding the date of the applicable Notice of Exercise or (z)&nbsp;the Bid Price of the Common Share on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder&#146;s execution of the applicable Notice of Exercise if
such Notice of Exercise is executed during &#147;regular trading hours&#148; on a Trading Day and is delivered within two (2)&nbsp;hours thereafter (including until two (2)&nbsp;hours after the close of &#147;regular trading hours&#148; on a Trading
Day) pursuant to Section&nbsp;2(a) hereof or (iii)&nbsp;the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to
Section&nbsp;2(a) hereof after the close of &#147;regular trading hours&#148; on such Trading Day; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(C) = the Exercise Price then in
effect for the applicable Warrant Shares at the time of such exercise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Warrant Shares are issued in such a cashless exercise, the
parties acknowledge and agree that in accordance with Section&nbsp;3(a)(9) of the Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company agrees not to take any position contrary
to this Section&nbsp;2(c). Notwithstanding anything to the contrary, without limiting the rights of the Holder to receive liquidated damages pursuant to Section&nbsp;2(d)(i) and Section&nbsp;2(d)(iv) herein, in the event the Company does not have or
maintain an effective registration statement, there are no circumstances that would require the Company to make any cash payments or net cash settle the purchase warrants to the holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Bid Price</U>&#148; means, for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the
Common Share is then listed or quoted on a Trading Market, the bid price of the Common Share for the time in question (or the nearest preceding date) on the Trading Market on which the Common Shares are then listed or quoted as reported by Bloomberg
L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Share for such date (or the nearest preceding date)
on OTCQB or OTCQX as applicable, (c)&nbsp;if the Common Share are not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Shares are then reported in the &#147;Pink Sheets&#148; published by OTC Markets Group, Inc. (or a
similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per Common Share so reported, or (d)&nbsp;in all other cases, the fair market value of a Common Share as determined by an independent
appraiser selected in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>VWAP</U>&#148; means, for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the Common
Shares are then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Shares for such date (or the nearest preceding date) on the Trading Market on which the Common Shares are then listed or quoted as reported
by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Share for such date (or the nearest preceding date) on
OTCQB or OTCQX as applicable, (c)&nbsp;if the Common Shares are not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Shares are then reported in the &#147;Pink Sheets&#148; published by OTC Markets Group, Inc. (or a
similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Shares so reported, or (d)&nbsp;in all other cases, the fair market value of a Common Share as determined by an
independent appraiser selected in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise
pursuant to this Section&nbsp;2(c). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) <U>Mechanics of Exercise</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">i. <U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be
transmitted by the Transfer Agent to the Holder by crediting the account of the Holder&#146;s or its designee&#146;s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&#147;<U>DWAC</U>&#148;) if
the Company is then a participant in such system and either (A)&nbsp;there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B)&nbsp;this Warrant is being
exercised via cashless exercise, and otherwise by physical delivery of a certificate, registered in the Company&#146;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled
pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earlier of (i)&nbsp;two (2) Trading Days and (ii)&nbsp;the number of Trading Days comprising the Standard Settlement Period after the
delivery to the Company of the Notice of Exercise (such date, the &#147;<U>Warrant Share Delivery Date</U>&#148;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of
the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received
within the earlier of (i)&nbsp;two (2) Trading Days and (ii)&nbsp;the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the
Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the
VWAP of the Common Shares on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant Share
Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used
herein, &#147;<U>Standard Settlement Period</U>&#148; means the standard settlement period, expressed in a number of Trading Days, on the Company&#146;s primary Trading Market with respect to the Common Shares as in effect on the date of delivery of
the Notice of Exercise. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">ii. <U>Delivery of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in
part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased
Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">iii. <U>Rescission Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares
pursuant to Section&nbsp;2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">iv. <U>Compensation for <FONT STYLE="white-space:nowrap">Buy-In</FONT> on Failure to Timely Deliver</U> Warrant Shares Upon
Exercise. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section&nbsp;2(d)(i) above pursuant to an exercise
on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&#146;s brokerage firm otherwise
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
purchases, Common Shares to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#147;<U><FONT
STYLE="white-space:nowrap">Buy-In</FONT></U>&#148;), then the Company shall (A)&nbsp;pay in cash to the Holder the amount, if any, by which (x)&nbsp;the Holder&#146;s total purchase price (including brokerage commissions, if any) for the Common
Shares so purchased exceeds (y)&nbsp;the amount obtained by multiplying (1)&nbsp;the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2)&nbsp;the price at which the sell
order giving rise to such purchase obligation was executed, and (B)&nbsp;at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such
exercise shall be deemed rescinded) or deliver to the Holder the number of Common Shares that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common
Shares having a total purchase price of $11,000 to cover a <FONT STYLE="white-space:nowrap">Buy-In</FONT> with respect to an attempted exercise of Common Shares with an aggregate sale price giving rise to such purchase obligation of $10,000, under
clause (A)&nbsp;of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the <FONT
STYLE="white-space:nowrap">Buy-In</FONT> and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&#146;s right to pursue any other remedies available to it hereunder, at law or in equity including,
without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#146;s failure to timely deliver the Common Shares upon exercise of the Warrant as required pursuant to the terms hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">v. <U>No Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the
exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount
equal to such fraction multiplied by the Exercise Price or round up to the next whole share. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">vi. <U>Charges, Taxes and
Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the
Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder;<U> provided</U>, <U>however</U>, that in the event that Warrant Shares are to be issued in a name other than the
name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse
it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for <FONT STYLE="white-space:nowrap">same-day</FONT> processing of any Notice of Exercise and all fees to the Depository Trust Company (or another
established clearing corporation performing similar functions) required for <FONT STYLE="white-space:nowrap">same-day</FONT> electronic delivery of the Warrant Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">vii. <U>Closing of Books</U>. The Company will not close its shareholder books or records in any manner which prevents the
timely exercise of this Warrant, pursuant to the terms hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">e) <U>Holder&#146;s Exercise Limitations</U>. The Company shall not effect
any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section&nbsp;2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the
applicable Notice of Exercise, the Holder (together with the Holder&#146;s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&#146;s Affiliates (such Persons, &#147;<U>Attribution Parties</U>&#148;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of Common Shares beneficially owned by the Holder and its Affiliates and Attribution Parties shall include
the number of Common Shares issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of Common Shares which would be issuable upon (i)&nbsp;exercise of the remaining, nonexercised
portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii)&nbsp;exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without
limitation, any other Common Shares Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties. Except as set forth in
the preceding sentence, for purposes of this Section&nbsp;2(e), beneficial ownership shall be calculated in accordance with Section&nbsp;13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section&nbsp;13(d) of the Exchange Act and the Holder is solely responsible for any
schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section&nbsp;2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder
together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&#146;s determination
of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership
Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section&nbsp;13(d) of the
Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section&nbsp;2(e), in determining the number of outstanding Common Shares, a Holder may rely on the number of outstanding Common Shares as reflected in
(A)&nbsp;the Company&#146;s most recent periodic or annual report filed with the Commission, as the case may be, (B)&nbsp;a more recent public announcement by the Company or (C)&nbsp;a more recent written notice by the Company or the Transfer Agent
setting forth the number of Common Shares outstanding. Upon the written or oral request of a Holder, the Company shall within one (1)&nbsp;Trading Day confirm orally and in writing to the Holder the number of Common Shares then outstanding. In any
case, the number of outstanding Common Shares shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of
which such number of outstanding Common Shares was reported. The &#147;<U>Beneficial Ownership Limitation</U>&#148; shall be [9.99/4.99%] of the number of Common Shares outstanding immediately after giving effect to the issuance of Common Shares
issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section&nbsp;2(e), provided that the Beneficial Ownership Limitation in no event exceeds
9.99% of the number of the Common Shares outstanding immediately after giving effect to the issuance of Common Shares upon exercise of this Warrant held by the Holder and the provisions of this Section&nbsp;2(e) shall continue to apply. Any increase
in the Beneficial Ownership Limitation will not be effective until the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with
the terms of this Section&nbsp;2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable
to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section<U></U>&nbsp;3. <U>Certain Adjustments</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i)&nbsp;pays a stock dividend or
otherwise makes a distribution or distributions on its Common Shares or any other equity or equity equivalent securities payable in Common Shares (which, for avoidance of doubt, shall not include any Common Shares issued by the Company upon exercise
of this Warrant), (ii) subdivides outstanding Common Shares into a larger number of shares, (iii)&nbsp;combines (including by way of reverse stock split) outstanding Common Shares into a smaller number of shares, or (iv)&nbsp;issues by
reclassification of Common Shares any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of Common Shares (excluding treasury shares, if any)
outstanding immediately before such event and of which the denominator shall be the number of Common Shares outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted
such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section&nbsp;3(a) shall become effective immediately after the record date for the determination of shareholders entitled to receive
such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or <FONT STYLE="white-space:nowrap">re-classification.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <U>Reserved</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c)
<U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section&nbsp;3(a) above, if at any time the Company grants, issues or sells any Common Shares Equivalents or rights to purchase stock, warrants, securities or other
property pro rata to the record holders of any class of Common Shares (the &#147;<U>Purchase Rights</U>&#148;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the
Holder could have acquired if the Holder had held the number of Common Shares acquirable upon </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a
record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of Common Shares are to be determined for the grant, issue or sale of such Purchase Rights (provided,
however, to the extent that the Holder&#146;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to
such extent (or beneficial ownership of such Common Shares as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not
result in the Holder exceeding the Beneficial Ownership Limitation). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) <U>Pro Rata Distributions</U>. During such time as this Warrant
is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of Common Shares, by way of return of capital or otherwise (including, without limitation, any
distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, plan of arrangement or other similar transaction) (a &#147;<U>Distribution</U>&#148;), at any time after
the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of Common Shares acquirable
upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no
such record is taken, the date as of which the record holders of Common Shares are to be determined for the participation in such Distribution (<U>provided</U>, <U>however</U>, to the extent that the Holder&#146;s right to participate in any such
Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any Common Shares as a result of such
Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">e) <U>Fundamental Transaction</U>. If, at any time while this Warrant is outstanding, (i)&nbsp;the Company, directly or indirectly, in
one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii)&nbsp;the Company, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition
of all or substantially all of its assets in one or a series of related transactions, (iii)&nbsp;any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which
holders of Common Shares are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Shares, (iv)&nbsp;the Company, directly or
indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Shares or any compulsory share exchange pursuant to which the Common Shares are effectively converted into or exchanged
for other securities, cash or property, or (v)&nbsp;the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a
reorganization, recapitalization, <FONT STYLE="white-space:nowrap">spin-off</FONT> or plan of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding Common Shares (not
including any Common Shares held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination) or 50% of the
voting power of the common equity of the Company (each a &#147;<U>Fundamental Transaction</U>&#148;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been
issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section&nbsp;2(e) on the exercise of this Warrant), the number of Common Shares of the
successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &#147;<U>Alternate Consideration</U>&#148;) receivable as a result of such Fundamental Transaction by a holder of the
number of Common Shares for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section&nbsp;2(e) on the exercise of this Warrant). For purposes of any such exercise, the
determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Shares in such Fundamental Transaction, and the
Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Shares are given any choice as to the
securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a
Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&#146;s option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later,
the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion
of this Warrant on the date of the consummation of such Fundamental Transaction; provided, however, that, if the Fundamental Transaction is not within the Company&#146;s control, including not approved by the Company&#146;s Board of Directors,
Holder shall only be entitled to receive from the Company or any Successor Entity, as of the date of consummation of such Fundamental Transaction, the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the
unexercised portion of this Warrant, that is being offered and paid to the holders of Common Shares of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof,
or whether the holders of Common Shares are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction; provided, further, that if holders of Common Shares of the Company are not offered
or paid any consideration in such Fundamental Transaction, such holders of Common Shares will be deemed to have received common stock of the Successor Entity (which Entity may be the Company following such Fundamental Transaction) in such
Fundamental Transaction. &#147;<U>Black Scholes Value</U>&#148; means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the &#147;OV&#148; function on Bloomberg, L.P. (&#147;Bloomberg&#148;) determined as of the
day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A)&nbsp;a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement
of the applicable Fundamental Transaction and the Termination Date, (B)&nbsp;an expected volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg (determined utilizing a 365 day annualization
factor) as of the Trading Day immediately following the public announcement of the applicable Fundamental Transaction, (C)&nbsp;the underlying price per share used in such calculation shall be the greater of (i)&nbsp;the sum of the price per share
being offered in cash, if any, plus the value of any <FONT STYLE="white-space:nowrap">non-cash</FONT> consideration, if any, being offered in such Fundamental Transaction and (ii)&nbsp;the greater of (x)&nbsp;the last VWAP immediately prior to the
public announcement of such Fundamental Transaction and (y)&nbsp;the last VWAP immediately prior to the consummation of such Fundamental Transaction and (D)&nbsp;a remaining option time equal to the time between the date of the public announcement
of the applicable Fundamental Transaction and the Termination Date and (E)&nbsp;a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds within five Business Days of the Holder&#146;s
election (or, if later, on the effective date of the Fundamental Transaction). The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &#147;<U>Successor Entity</U>&#148;) to assume in
writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section&nbsp;3(e) pursuant to written agreements in form and substance reasonably satisfactory to the
Holder prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance
to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the Common Shares acquirable and receivable upon exercise of this Warrant (without regard to any
limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the Common
Shares pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to
the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so
that from and after the date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring to the &#147;Company&#148; shall refer instead to the Successor Entity), and may exercise every right and
power of the Company and shall assume all of the obligations of the Company under this Warrant and the other Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">f) <U>Calculations</U>. All calculations under this Section&nbsp;3 shall be made to the nearest cent or the nearest 1/100th of a share, as the
case may be. For purposes of this Section&nbsp;3, the number of Common Shares deemed to be issued and outstanding as of a given date shall be the sum of the number of Common Shares (excluding treasury shares, if any) issued and outstanding. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">g) <U>Notice to Holder</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">i. <U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this
Section&nbsp;3, the Company shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement
of the facts requiring such adjustment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">ii. <U>Notice to Allow Exercise by Holder</U>. If (A)&nbsp;the Company shall
declare a dividend (or any other distribution in whatever form) on the Common Shares, (B)&nbsp;the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Shares, (C)&nbsp;the Company shall authorize the granting
to all holders of the Common Shares rights or warrants to subscribe for or purchase any capital stock of any class or of any rights, (D)&nbsp;the approval of any shareholders of the Company shall be required in connection with any reclassification
of the Common Shares, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Shares are converted into other
securities, cash or property, (E)&nbsp;the Company effects a Fundamental Transaction or (F)&nbsp;the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the
Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email address as it shall appear upon the Warrant Register of the Company, at least 5 calendar days prior to the applicable record or effective
date hereinafter specified, a notice stating (x)&nbsp;the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of
the Common Shares of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y)&nbsp;the date on which such reclassification, consolidation, merger, sale, transfer or stock exchange or
Fundamental Transaction is expected to become effective or close, and the date as of which it is expected that holders of the Common Shares of record shall be entitled to exchange their Common Shares for securities, cash or other property
deliverable upon such reclassification, consolidation, merger, sale, transfer or stock exchange or Fundamental Transaction; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the
validity of the corporate action required to be specified in such notice and provided, further that no notice shall be required if the information is disseminated in a press release or document filed with the Securities and Exchange Commission . To
the extent that any notice provided in this Warrant constitutes, or contains, material, <FONT STYLE="white-space:nowrap">non-public</FONT> information regarding the Company, the Company shall file such notice with the Commission pursuant to a
Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> as soon as practicable thereafter. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the
event triggering such notice except as may otherwise be expressly set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section 4. <U>Transfer of Warrant</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <U>Transferability</U>. This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in
whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or
attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or
assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be
cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this
Warrant to the Company within three (3)&nbsp;Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new
holder for the purchase of Warrant Shares without having a new Warrant issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <U>New Warrants</U>. This Warrant may be divided or
combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or
attorney. Subject to compliance with Section&nbsp;4(a), as to any transfer which may be involved in such division or combination, the Company shall execute </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be
dated the Issue Date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) <U>Warrant Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the
&#147;<U>Warrant Register</U>&#148;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any
distribution to the Holder, and for all other purposes, absent actual notice to the contrary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section<U></U>&nbsp;5. <U>Miscellaneous</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <U>No Rights as Shareholder Until Exercise</U>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as
a shareholder of the Company prior to the exercise hereof as set forth in Section&nbsp;2(d)(i), except as expressly set forth in Section&nbsp;3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in
the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated
as of such cancellation, in lieu of such Warrant or stock certificate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) <U>Saturdays, Sundays, Holidays, etc</U>. If the last or
appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business Day. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) <U>Authorized Shares</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Shares a
sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its
officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may
be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Shares may be listed. The Company covenants that all Warrant Shares which may be issued upon the
exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and
nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of continuance or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms
of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against
impairment. Without limiting the generality of the foregoing, the Company will (i)&nbsp;not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value,
(ii)&nbsp;take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii)&nbsp;use commercially reasonable
efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before taking any action which would result in an adjustment in the number of Warrant Shares
for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">e) <U>Jurisdiction</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be
determined in accordance with the provisions of the Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">f) <U>Restrictions</U>. The Holder acknowledges that the Warrant
Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">g) <U>Nonwaiver and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall
operate as a waiver of such right or otherwise prejudice the Holder&#146;s rights, powers or remedies, notwithstanding the fact that the Holder&#146;s right to exercise this Warrant terminates on the Termination Date. If the Company willfully and
knowingly fails to comply with any provision of this Warrant or the Purchase Agreement, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses
including, but not limited to, reasonable attorneys&#146; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">h) <U>Notices</U>. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company
shall be delivered in accordance with the notice provisions of the Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">i) <U>Limitation of Liability</U>. No provision
hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Common Shares or as a shareholder of the Company, whether such liability is asserted by the Company or by creditors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">j) <U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be
entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to
waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">k) <U>Successors and
Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted
assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">l) <U>Amendment</U>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the
Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">m) <U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective
and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of
such provisions or the remaining provisions of this Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">n) <U>Headings</U>. The headings used in this Warrant are for the
convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">******************** </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Signature Page Follows) </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer
thereunto duly authorized as of the date first above indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>VILLAGE FARMS INTERNATIONAL, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF EXERCISE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>TO: VILLAGE FARMS
INTERNATIONAL, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(1) The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached
Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2)
Payment shall take the form of (check applicable box): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#9744; in lawful money of the United States; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#9744; if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to
exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(3) Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="64%"></TD></TR>


<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Warrant Shares shall be delivered to the following DWAC Account Number: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="64%"></TD></TR>


<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(4) Accredited Investor. The undersigned is an &#147;accredited investor&#148; as defined in Regulation D promulgated under
the Securities Act of 1933, as amended. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD></TR>


<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[SIGNATURE OF HOLDER]</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name of Investing Entity:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Signature of Authorized Signatory of Investing Entity:</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name of Authorized Signatory:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title of Authorized Signatory:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ASSIGNMENT FORM </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(To assign the foregoing
Warrant, execute this form and supply required information. Do not use this form to purchase shares.) </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FOR VALUE RECEIVED, the foregoing Warrant and
all rights evidenced thereby are hereby assigned to </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>(Please Print)</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>(Please Print)</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Phone Number:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Email Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Dated: _______________ __, ______</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Holder&#146;s Signature:______________________</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Holder&#146;s Address:______________________</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>d369529dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="27%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">


<IMG SRC="g369529g23d36.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">1114&nbsp;Avenue&nbsp;of&nbsp;the&nbsp;Americas,&nbsp;23rd&nbsp;Floor</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">New York, New York 10036.7703 USA</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">P. 212.880.6000&nbsp;&nbsp;|&nbsp;&nbsp;F.
212.682.0200</P> <P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">79 Wellington St. W., 30th Floor</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">Box 270, TD South Tower</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">Toronto, Ontario M5K 1N2 Canada</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">P. 416.865.0040&nbsp;&nbsp;|&nbsp;&nbsp;F. 416.865.7380</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL"><FONT COLOR="#0000ff"><U>www.torys.com</U></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">January&nbsp;30, 2023 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Village
Farms International, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4700-80th Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Delta, British
Columbia, Canada </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">V4K 3N3 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Sirs/Mesdames: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>&nbsp;&nbsp;&nbsp;&nbsp;Re: Village Farms International, Inc. &#150; Registered Direct Offering of Common Shares and Warrants </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have acted as U.S. and Canadian counsel for Village Farms International, Inc., a corporation organized under the laws of the Province of
Ontario (the &#147;<B>Corporation</B>&#148;), in connection with the registration of 18,350,000 common shares in the capital of the Corporation (each, a &#147;<B>Common Share</B>&#148;) and 18,350,000 warrants, with each warrant exercisable to
purchase one (1)&nbsp;Common Share (each, a &#147;<B>Warrant</B>&#148; and each Common Share underlying a Warrant, a &#147;<B>Warrant Share</B>&#148;), pursuant to the prospectus supplement, dated January&nbsp;26, 2023, to the prospectus included as
part of a registration statement (the &#147;<B>Registration Statement</B>&#148;) on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (No. <FONT STYLE="white-space:nowrap">333-257857),</FONT> filed on July&nbsp;12, 2021 and amended on June&nbsp;9,
2022 by the Corporation and declared effective on June&nbsp;21, 2022 by the Securities and Exchange Commission (the &#147;<B>Commission</B>&#148;) under the Securities Act of 1933, as amended (the &#147;<B>Securities Act</B>&#148;). The Common
Shares and Warrants will be sold and issued all in accordance with one or more Securities Purchase Agreements, each dated January&nbsp;26, 2023, by and among the Corporation and the purchasers identified therein (the &#147;<B>Securities Purchase
Agreements</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are qualified to practice law in the Province of Ontario and the State of New York, and we do not express any
opinion with respect to the laws of any jurisdiction other than (a)&nbsp;the laws of the Province of Ontario and the federal laws of Canada applicable therein (including in respect of the <I>Business Corporations Act</I> (Ontario) (the
&#147;<B>OBCA</B>&#148;)), and (b)&nbsp;the laws of the State of New York, in each case, in force at the date of this opinion letter. All opinions with respect to the laws of the Province of Ontario and the federal laws of Canada applicable therein
are given by members of the Law Society of Ontario and all opinions with respect to the laws of the State of New York are given by members of the New York State Bar. Notwithstanding the foregoing and our opinions set forth below, we express no
opinion with respect to the compliance or <FONT STYLE="white-space:nowrap">non-compliance</FONT> with applicable privacy laws in connection with the issuance and sale of any Common Shares or Warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As counsel for the Corporation, we have examined originals or copies, certified or otherwise identified to our satisfaction, of such
documents, corporate records, certificates of public officials and other instruments as we have deemed necessary for the purposes of rendering this opinion and we are familiar with the proceedings taken and proposed to be taken by the Corporation in
connection with the authorization, issuance and sale of the Common Shares and Warrants. In our examination, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals and the conformity with the
originals of all documents submitted to us as copies. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon the foregoing, and subject to the foregoing qualifications, assumptions and
limitations and the further limitations set forth below, we are of the opinion that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. The Common Shares have been duly authorized for
issuance and, when issued and paid for in accordance with the terms set forth in the Securities Purchase Agreements, will be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. The Warrants have been duly authorized and, when issued and paid for in accordance with the terms set forth in the Securities Purchase
Agreements, will constitute valid and legally binding obligations of the Corporation enforceable against the Corporation in accordance with their terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. The Warrant Shares issuable upon exercise of the Warrants have been duly authorized for issuance and, when issued upon exercise of the
Warrants in accordance with the terms thereof, will be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our opinion expressed in paragraph 2 is subject to the following qualifications and exceptions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any applicable bankruptcy, insolvency, moratorium, arrangement,
<FONT STYLE="white-space:nowrap">winding-up</FONT> laws or similar laws affecting the enforcement of creditors&#146; rights generally including laws regarding limitations of action; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">concepts of reasonableness and general principles of equity, including the principle that the granting of
equitable remedies such as specific performance and injunctive relief is within the discretion of a court of competent jurisdiction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the powers of a court of competent jurisdiction to grant relief from forfeiture, to stay proceedings before it
and to stay execution on judgments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the qualification that the costs of and incidental to all proceedings authorized to be taken in court are in
the discretion of the court and the court has full power to determine by whom and to what extent such costs shall be paid; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the qualification that a court may require the discretionary powers expressed to be conferred on any party to
such agreement or certificate to be exercised reasonably and in good faith notwithstanding any provisions to the contrary and may decline to accept as conclusive factual or legal determinations described as conclusive therein; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the qualification that any provision in such agreement or certificate which purports to sever from such
agreement or certificate, as the case may be, any provision therein which is prohibited or unenforceable under applicable law without affecting the validity of the remainder of the agreement or certificate, as the case may be, would be enforced only
to the extent that the court determined that such prohibited or unenforceable provision could be severed without impairing the interpretation and application of the remainder of the agreement or certificate, as the case may be; and
</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the qualification that any provision in such agreement or certificate which purports to exculpate a party from
liability or duty otherwise owed by it to another and certain remedial terms and waivers of equitable defenses provided for in such agreement or certificate are limited by law. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We express no opinion as to (i)&nbsp;the enforceability of any waiver of rights under any usury or stay law or (ii)&nbsp;the effect of
fraudulent conveyance, fraudulent transfer or similar provision of applicable law on the conclusions expressed above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have also
assumed that neither the issuance and delivery of the Warrants, nor the compliance by the Corporation with the terms of the Warrants, will violate any applicable law or public policy or will result in a violation of any provision of any instrument
or agreement then binding upon the Corporation, or any restriction imposed by any court or governmental body having jurisdiction over the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, our opinions expressed above are subject to the qualifications that we express no opinion as to the applicability of, compliance
with, or effect of any laws except the OBCA and, in the case of paragraph 2, the laws of the State of New York. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We consent to the use of
this opinion as an exhibit to the Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> to be filed by the Corporation with the Commission on January&nbsp;30, 2023 and its incorporation by reference in the Registration Statement. In
giving this consent, we do not admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Securities Act or the rules and regulations of the Commission thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Torys LLP </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>5
<FILENAME>d369529dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF SECURITIES PURCHASE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Securities Purchase Agreement (this &#147;<U>Agreement</U>&#148;) is dated as of January&nbsp;26, 2023, between Village Farms International, Inc., a
corporation continued under the laws of the Province of Ontario (the &#147;<U>Company</U>&#148;), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a &#147;<U>Purchaser</U>&#148; and
collectively the &#147;<U>Purchasers</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective
registration statement under the Securities Act of 1933, as amended (the &#147;<U>Securities Act</U>&#148;), the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the
Company, the securities as more fully described in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement,
and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">DEFINITIONS
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.1 <U>Definitions</U>. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the
meanings set forth in this Section&nbsp;1.1: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>A.G.P.</U>&#148; means A.G.P./Alliance Global Partners, as <FONT
STYLE="white-space:nowrap">co-lead</FONT> placement agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Acquiring Person</U>&#148; shall have the meaning ascribed to such
term in Section&nbsp;4.5. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Action</U>&#148; shall have the meaning ascribed to such term in Section&nbsp;3.1(j). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Affiliate</U>&#148; means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or
is under common control with a Person as such terms are used in and construed under Rule 405 under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Board of
Directors</U>&#148; means the board of directors of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Business Day</U>&#148; means any day except any Saturday, any
Sunday, any day which is a federal legal holiday in the United States or any day on which banking institutions in the State of New York or Vancouver, British Columbia are authorized or required by law or other governmental action to close. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Canadian Jurisdictions</U>&#148; means each of the provinces and territories of Canada. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Canadian Authorities</U>&#148; means the Canadian securities regulatory authorities in each of the Canadian Jurisdictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Canadian Securities Laws</U>&#148; means the rules and procedures established under all applicable securities laws in each of the
Canadian Jurisdictions and the respective regulations and rules under such laws together with applicable published policies, policy statements, instruments, blanket orders, blanket rulings and notices of the securities regulatory authorities in the
Canadian Jurisdictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Cantor</U>&#148; means Cantor Fitzgerald&nbsp;&amp; Co., as
<FONT STYLE="white-space:nowrap">co-lead</FONT> placement agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>CFPOA</U>&#148; means the Corruption of Foreign Public
Officials Act (Canada). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Closing</U>&#148; means the closing of the purchase and sale of the Shares and Warrants pursuant to
Section&nbsp;2.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Closing Date</U>&#148; means the Trading Day on which all of the Transaction Documents have been executed and
delivered by the applicable parties thereto, and all conditions precedent to (i)&nbsp;the Purchasers&#146; obligations to pay the Subscription Amount and (ii)&nbsp;the Company&#146;s obligations to deliver the Shares and Warrants, in each case, have
been satisfied or waived, but in no event later than the second (2nd) Trading Day following the date hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Commission</U>&#148; means the United States Securities and Exchange Commission. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Common Shares</U>&#148; means the common shares of the Company, no par value, and
any other class of securities into which such securities may hereafter be reclassified or changed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Common Shares
Equivalents</U>&#148; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Shares, including, without limitation, any debt, preferred shares, right, option, warrant or other
instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Common Warrants</U>&#148; means, collectively, the Common Share purchase warrants delivered to the Purchasers at the Closing in
accordance with Section&nbsp;2.2(a) hereof, which Common Warrants shall be exercisable 6 months after the date of issuance and have a term of exercise equal to five (5)&nbsp;years from the initial exercise date, in the form of <U>Exhibit A</U>
attached hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Counsel</U>&#148; means Torys LLP, with offices located at New York, New York and Toronto, Canada. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Disclosure Schedules</U>&#148; means the Disclosure Schedules of the Company delivered concurrently herewith, if any. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Disclosure Time</U>&#148; means, (i)&nbsp;if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m. (New York
City time) and before midnight (New York City time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following the date hereof, unless otherwise instructed as to an earlier time by A.G.P., and (ii)&nbsp;if this
Agreement is signed between midnight (New York City time) and 9:00 a.m. (New York City time) on any Trading Day, no later than 9:01 a.m. (New York City time) on the date hereof, unless otherwise instructed as to an earlier time by A.G.P. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Evaluation Date</U>&#148; shall have the meaning ascribed to such term in Section&nbsp;3.1(s). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Exchange Act</U>&#148; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Exempt Issuance</U>&#148; means the issuance of (a)&nbsp;Shares as contemplated by this Agreement, (b)&nbsp;Common Shares,
options restricted share units (or any other securities issuable under the Company&#146;s Amended and Restated Share-Based Compensation Plan, dated March&nbsp;15, 2021 and adopted June&nbsp;10, 2021 (the &#147;<B>Equity Plan</B>&#148;)) to
employees, officers, consultants or directors of the Company or Common Shares issuable upon the exercise or vesting of any such securities issuable pursuant to the Equity Plan or any such securities issuable under any similar arrangement duly
adopted for such purpose, by a majority of the <FONT STYLE="white-space:nowrap">non-employee</FONT> members of the Board of Directors or a majority of the members of a committee of <FONT STYLE="white-space:nowrap">non-employee</FONT> directors
established for such purpose for services rendered to the Company, (c)&nbsp;securities upon the exercise or exchange of or conversion of any securities exercisable or exchangeable for or convertible into Common Shares issued and outstanding on the
date of this Agreement, provided that such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities (other
than in connection with stock splits or combinations or anti-dilution provisions contained therein and disclosed in the SEC Reports) or to extend the term of such securities, (d)&nbsp;Common Shares issuable upon exercise of the Put/Call Option (as
defined in the Prospectus), (e) Common Shares pursuant to a <FONT STYLE="white-space:nowrap">&#147;10b5-1&#148;</FONT> trading plan that is in existence as of the date hereof, and (f)&nbsp;securities issued pursuant to acquisitions or strategic
transactions approved by a majority of the disinterested directors of the Company, provided that any such issuance shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital and provided
further that such securities are issued as &#147;restricted securities&#148; (as defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement in connection therewith during the prohibition
period in Section&nbsp;4.12(a) herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>FCPA</U>&#148; means the Foreign Corrupt Practices Act of 1977, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>FDA</U>&#148; shall have the meaning ascribed to such term in Section&nbsp;3.1(hh). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>FDCA</U>&#148; shall have the meaning ascribed to such term in Section&nbsp;3.1(hh). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>GAAP</U>&#148; shall have the meaning ascribed to such term in Section&nbsp;3.1(h). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Health Canada</U>&#148; means the Canadian federal Department of Health and any successor thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Indebtedness</U>&#148; shall have the meaning ascribed to such term in Section&nbsp;3.1(aa). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Intellectual Property Rights</U>&#148; shall have the meaning ascribed to such term in Section&nbsp;3.1(p). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Liens</U>&#148; means a lien, charge, pledge, security interest, encumbrance, right
of first refusal, preemptive right or other restriction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement</U>&#148;
means the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, dated as of the date hereof, by and among the Company and the directors and officers of the Company, in the form of <U>Exhibit B </U>attached hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Material Adverse Effect</U>&#148; shall have the meaning assigned to such term in Section&nbsp;3.1(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Material Permits</U>&#148; shall have the meaning ascribed to such term in Section&nbsp;3.1(n). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Per Share Purchase Price</U>&#148; equals $1.35 per Share and accompanying Common Warrant, subject to adjustment for reverse and
forward stock splits, stock dividends, stock combinations and other similar transactions of Common Shares that occur between the date hereof and the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Person</U>&#148; means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture,
limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Pharmaceutical Product</U>&#148; shall have the meaning ascribed to such term in Section&nbsp;3.1(hh). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Placement Agents</U>&#148; means A.G.P. and Cantor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Placement Agent Agreement</U>&#148; means that certain placement agent agreement dated as of the date hereof between the Company,
A.G.P. and Cantor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Proceeding</U>&#148; means an action, claim, suit, investigation or proceeding (including, without
limitation, an informal investigation or partial proceeding, such as a deposition) pending or, to the Company&#146;s knowledge, threatened in writing against or affecting the Company, any Subsidiary or any of their respective properties before or by
any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Prospectus</U>&#148; means the Company&#146;s base prospectus included in the Registration Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Prospectus Supplement</U>&#148; means the Company&#146;s supplement to the Prospectus in respect of the placement of the Shares and
Warrants complying with Rule 424(b) of the Securities Act that is filed with the Commission and delivered by the Company to each Purchaser at the Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Purchaser Party</U>&#148; shall have the meaning ascribed to such term in Section&nbsp;4.8. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Registration Statement</U>&#148; means the Company&#146;s effective registration statement with Commission (File <FONT
STYLE="white-space:nowrap">No.&nbsp;333-257857),</FONT> which registers the offer and sale from time to time of Common Shares and the other securities identified therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Required Approvals</U>&#148; shall have the meaning ascribed to such term in Section&nbsp;3.1(e). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Rule 144</U>&#148; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or
interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Rule 424</U>&#148; means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or
interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>SEC Reports</U>&#148; shall have the meaning ascribed to such term in Section&nbsp;3.1(h). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Securities</U>&#148; means the Shares, the Warrants and the Warrant Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Securities Act</U>&#148; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Shares</U>&#148; means the Common Shares issued or issuable to each Purchaser pursuant to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Short Sales</U>&#148; means all &#147;short sales&#148; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall
not be deemed to include locating and/or borrowing Common Shares). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Subscription Amount</U>&#148; means, as to each Purchaser, the aggregate amount to
be paid for Shares and Warrants purchased hereunder as specified below such Purchaser&#146;s name on the signature page of this Agreement and next to the heading &#147;Subscription Amount,&#148; in United States dollars and in immediately available
funds. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Subsidiary</U>&#148; means any subsidiary of the Company as set forth on the SEC Reports, and shall, where applicable,
also include any direct or indirect subsidiary of the Company formed or acquired after the date hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Trading Day</U>&#148;
means a day on which the principal Trading Market is open for trading. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Trading Market</U>&#148; means the following markets or
exchanges on which the Common Shares are listed or quoted for trading on the date in question: The Nasdaq Stock Market LLC (&#147;<U>Nasdaq</U>&#148;) (or any successors to the foregoing). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Transaction Documents</U>&#148; means this Agreement, the Warrants, the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements,
the Placement Agent Agreement and all exhibits and schedules thereto and hereto and any other documents or agreements executed in connection with the transactions contemplated hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Transfer Agent</U>&#148; means Computershare Investor Services Inc., the principal transfer agent of the Company, at its principal
offices in Vancouver, British Columbia or Toronto, Ontario, Continental Stock Transfer&nbsp;&amp; Trust Company, the U.S. transfer agent of the Company, at its principal offices in New York, New York, and any successor transfer agent of the Company.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Warrants</U>&#148; means the Common Warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Warrant Shares</U>&#148; means the Common Shares issuable upon exercise of the Warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Wholly-Owned Subsidiaries</U>&#148; means the Subsidiaries that are 100% owned by the Company, as indicated in the SEC Reports. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.2 <U>Currency</U>. All references in this Agreement to &#147;$&#148; shall refer to the currency of the United States of America, unless otherwise
specified. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PURCHASE AND SALE </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.1 <U>Closing</U>. On the
Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees to sell, and the Purchasers, severally and not jointly, agree to purchase, up to an aggregate of approximately $25&nbsp;million of Shares and Warrants.
Each Purchaser&#146;s Subscription Amount as set forth on the signature page hereto executed by such Purchaser shall be made available for &#147;Delivery Versus Payment&#148; settlement with the Company or its designees. The Company shall deliver to
each Purchaser its respective Shares as determined pursuant to Section&nbsp;2.2(a), and the Company and each Purchaser shall deliver the other items set forth in Section&nbsp;2.2 deliverable at the Closing. Upon satisfaction of the covenants and
conditions set forth in Sections 2.2 and 2.3, the Closing shall occur electronically or in such other manner as the parties shall mutually agree. Unless otherwise directed by the applicable Placement Agent, settlement of the Shares shall occur via
&#147;Delivery Versus Payment&#148; (i.e., on the Closing Date, the Company shall issue the Shares registered in the Purchasers&#146; names and addresses and released by the Transfer Agent directly to the account(s) at the applicable Placement Agent
identified by each Purchaser; upon receipt of such Shares, the applicable Placement Agent shall promptly electronically deliver such Shares to the applicable Purchaser, and payment therefor shall be made by the applicable Placement Agent (or a
clearing firm) by wire transfer to the Company). Notwithstanding anything herein to the contrary, if at any time on or after the time of execution of this Agreement by the Company and an applicable Purchaser through the Closing (the &#147;<U><FONT
STYLE="white-space:nowrap">Pre-Settlement</FONT> Period</U>&#148;), such Purchaser sells to any Person all, or any portion, of any Shares to be issued hereunder to such Purchaser at the Closing (collectively, the &#147;<U><FONT
STYLE="white-space:nowrap">Pre-Settlement</FONT> Shares</U>&#148;), such Person shall, automatically hereunder (without any additional required actions by such Purchaser or the Company), be deemed to be a Purchaser (the &#147;<U>Replacement
Purchaser</U>&#148;) under this Agreement unconditionally bound to purchase, and the Company shall be deemed unconditionally bound to sell, such <FONT STYLE="white-space:nowrap">Pre-Settlement</FONT> Shares to such Replacement Purchaser at the
Closing; provided, that the Company shall not be required to deliver any <FONT STYLE="white-space:nowrap">Pre-Settlement</FONT> Shares to such Replacement Purchaser prior to the Company&#146;s receipt of (1)&nbsp;the Subscription Amount for such <FONT
STYLE="white-space:nowrap">Pre-Settlement</FONT> Shares hereunder and (2)&nbsp;delivery instructions for such Replacement Purchaser that are reasonably acceptable to the Company, the Placement Agent for such Replacement Purchaser and the Transfer
Agent; provided, further, that the Company hereby acknowledges and agrees that the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
forgoing shall not constitute a representation or covenant by such Purchaser as to whether or not such Purchaser will elect to sell any <FONT STYLE="white-space:nowrap">Pre-Settlement</FONT>
Shares during the <FONT STYLE="white-space:nowrap">Pre-Settlement</FONT> Period. In addition, it is understood and agreed that no Replacement Purchaser can be resident or domiciled in Canada. The decision to sell any Shares will be made in the sole
discretion of such Purchaser from time to time, including during the <FONT STYLE="white-space:nowrap">Pre-Settlement</FONT> Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.2
<U>Deliveries</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) On or prior to the Closing Date, the Company shall deliver or cause to be delivered to each Purchaser the
following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) this Agreement duly executed by the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) a legal opinion, and negative assurance letter, of Company Counsel, in a form reasonably acceptable to the Purchasers and the Placement
Agents; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) the Company shall have provided each Purchaser with the Company&#146;s wire instructions, on Company letterhead and
executed by the Chief Executive Officer or Chief Financial Officer; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) subject to the last sentence of Section&nbsp;2.1, a copy of the
irrevocable instructions to the Transfer Agent instructing the Transfer Agent to deliver on an expedited basis via the Depository Trust Company Deposit or Withdrawal at Custodian system (&#147;<U>DWAC</U>&#148;) Shares equal to such Purchaser&#146;s
Subscription Amount divided by the Per Share Purchase Price, registered in the name of such Purchaser; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) a Common Warrant registered in
the name of such Purchaser to purchase up to a number of Warrant Shares equal to 100% of such Purchaser&#146;s shares of Common Shares, as applicable, with an exercise price equal to $1.65 per share, subject to adjustment therein; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) the duly executed <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) the Prospectus Supplement (which may be delivered in accordance with Rule 172 under the Securities Act). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) On or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) this Agreement duly executed by such Purchaser; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) such Purchaser&#146;s Subscription Amount with respect to the Securities, which shall be made available for &#147;Delivery Versus
Payment&#148; settlement with the Company or its designees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.3 <U>Closing Conditions</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse
Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Purchasers contained herein (unless as of a specific date therein in which case they shall be accurate as of such date); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) all obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been
performed; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) the delivery by each Purchaser of the items set forth in Section&nbsp;2.2(b) of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being met:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material
Adverse Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein (unless as of a specific date therein in which case they shall be accurate as of such date); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) all obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been
performed; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) the delivery by the Company of the items set forth in Section&nbsp;2.2(a) of this
Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) there shall have been no Material Adverse Effect with respect to the Company since the date hereof; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) from the date hereof to the Closing Date, trading in the Common Shares shall not have been suspended by the Commission or the
Company&#146;s principal Trading Market (other than a normal course temporary market halt in connection with the public announcement of the matters contemplated by this Agreement), and, at any time prior to the Closing Date, trading in securities
generally as reported by Bloomberg L.P. shall not have been suspended or limited (other than a normal course temporary market halt in connection with the public announcement of the matters contemplated by this Agreement), or minimum prices shall not
have been established on securities whose trades are reported by such service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities nor shall there have occurred any
material outbreak or escalation of hostilities or other national or international calamity of such magnitude in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of such Purchaser,
makes it impracticable or inadvisable to purchase the Securities at the Closing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">REPRESENTATIONS AND WARRANTIES </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.1
<U>Representations and Warranties of the Company</U>. Except as set forth in the SEC Reports, or in the Disclosure Schedules, which Disclosure Schedules shall be deemed a part hereof and shall qualify any representation or warranty otherwise made
herein to the extent of the disclosure contained in the corresponding section of the Disclosure Schedules, the Company hereby makes the following representations and warranties to each Purchaser: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) <U>Subsidiaries</U>. All of the direct and indirect subsidiaries of the Company are set forth in the SEC Reports. Except as set forth in the SEC Reports,
the Company owns, directly or indirectly, all of the capital stock or other equity interests of each Wholly-Owned Subsidiary free and clear of any Liens, and all of the issued and outstanding shares of capital stock of each Wholly-Owned Subsidiary
are validly issued and are fully paid, <FONT STYLE="white-space:nowrap">non-assessable</FONT> and free of preemptive and similar rights to subscribe for or purchase securities, other than such preemptive rights that have been waived. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) <U>Organization and Qualification</U>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing
and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company
nor any Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to
conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be so
qualified or in good standing, as the case may be, could not have or reasonably be expected to result in: (i)&nbsp;a material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii)&nbsp;a material adverse effect
on the results of operations, assets, business, prospects or condition (financial or otherwise) of the Company and the Subsidiaries, taken as a whole, or (iii)&nbsp;a material adverse effect on the Company&#146;s ability to perform in any material
respect on a timely basis its obligations under any Transaction Document to which it is a party (any of (i), (ii) or (iii), a &#147;<U>Material Adverse Effect</U>&#148;); provided that a change in the market price or trading volume of the Common
Shares alone shall not be deemed, in and of itself, to constitute a Material Adverse Effect. No Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority
or qualification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) <U>Authorization; Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the
transactions contemplated by this Agreement and each of the other Transaction Documents to which it is a party and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of this Agreement and each of the other
applicable Transaction Documents by the Company and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no further action is required by the
Company, the Board of Directors or the Company&#146;s shareholders in connection herewith or therewith other than in connection with the Required Approvals. This Agreement and each other Transaction Document to which it is a party has been (or upon
delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms,
except (i)&nbsp;as limited by </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&#146; rights generally,
(ii)&nbsp;as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii)&nbsp;insofar as indemnification and contribution provisions may be limited by applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) <U>No Conflicts</U>. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to which it is a party,
the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby do not and will not (i)&nbsp;conflict with or violate any provision of the Company&#146;s or any Subsidiary&#146;s certificate or
articles of incorporation, bylaws or other organizational or charter documents, or (ii)&nbsp;conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any
Lien upon any of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments, acceleration or cancellation (with or without notice, lapse of time or both)
of, any agreement, credit facility, debt or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which any property or asset of the Company or any
Subsidiary is bound or affected, or (iii)&nbsp;subject to the Required Approvals, conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to
which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii)&nbsp;and
(iii), such as could not have or reasonably be expected to result in a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(e) <U>Filings, Consents and Approvals</U>. The Company
is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in connection with the
execution, delivery and performance by the Company of the Transaction Documents to which it is a party, other than: (i)&nbsp;the filings required pursuant to Section&nbsp;4.4 of this Agreement, (ii)&nbsp;the filing with the Commission of the
Prospectus Supplement, (iii)&nbsp;application(s) to each applicable Trading Market for the listing of the Shares for trading thereon in the time and manner required thereby, (iv)&nbsp;such filings as are required to be made under applicable state
securities laws, and (v)&nbsp;any ordinary course report of distribution and similar filings with certain Canadian Authorities related hereto (collectively, the &#147;<U>Required Approvals</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(f) <U>Issuance of the Securities; Registration</U>. The Shares and Warrants have been duly authorized and, when issued and paid for in accordance with the
applicable Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company. The Warrants are duly authorized and, when issued in accordance with this Agreement, will be duly
and validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable,</FONT> and free and clear of all Liens imposed by the Company. The Company has reserved from its duly authorized capital stock the number of Common Shares issuable
pursuant to this Agreement and the Warrants. The Company has prepared and filed the Registration Statement in conformity with the requirements of the Securities Act, which became effective on June&nbsp;21, 2022 (the &#147;<U>Effective
Date</U>&#148;), including the Prospectus, and such amendments and supplements thereto as may have been required to the date of this Agreement. The Company was at the time of the filing of the Registration Statement eligible to use Form <FONT
STYLE="white-space:nowrap">S-3.</FONT> The Company is eligible to use Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act and it meets the transaction requirements as set forth in General Instruction I.B.1 of Form <FONT
STYLE="white-space:nowrap">S-3.</FONT> The Registration Statement is effective under the Securities Act and no stop order preventing or suspending the effectiveness of the Registration Statement or suspending or preventing the use of the Prospectus
has been issued by the Commission and no proceedings for that purpose have been instituted or, to the knowledge of the Company, are threatened by the Commission. The Company, if required by the rules and regulations of the Commission, shall file the
Prospectus Supplement with the Commission pursuant to Rule 424(b). At the time the Registration Statement and any amendments thereto became effective, at the date of this Agreement and at the Closing Date, the Registration Statement and any
amendments thereto conformed and will conform in all material respects to the requirements of the Securities Act and did not and will not contain any untrue statement of a material fact or omit to state any material fact required to be stated
therein or necessary to make the statements therein not misleading; and the Prospectus and any amendments or supplements thereto, at the time the Prospectus or any amendment or supplement thereto was issued and at the Closing Date, conformed and
will conform in all material respects to the requirements of the Securities Act and did not and will not contain an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light
of the circumstances under which they were made, not misleading. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(g) <U>Capitalization</U>. The capitalization of the Company as of the date hereof is as set forth on
<U>Schedule 3.1(g)</U>, which Schedule 3.1(g) shall also include the number of Common Shares owned beneficially, and of record, by Affiliates of the Company as of the date hereof. The Company has not issued any capital stock since its most recently
filed periodic report under the Exchange Act, other than pursuant to the exercise of employee stock options or in connection with the vesting of restricted share units under the Equity Plan, the issuance of Common Shares to employees pursuant to the
Company&#146;s employee stock purchase plans, pursuant to the conversion and/or exercise of Common Share Equivalents outstanding as of the date of the most recently filed periodic report under the Exchange Act and pursuant to the Company&#146;s <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;at-the-market&#148;</FONT></FONT> equity program, in accordance with the terms of the Controlled Equity Offering Sales Agreement, dated August&nbsp;9, 2022, between the Company and
Cantor Fitzgerald&nbsp;&amp; Co. and A.G.P./Alliance Global Partners. No Person has any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated by the Transaction
Documents, except which have been waived. Except as set forth on <U>Schedule 3.1(g)</U> and as a result of the purchase and sale of the Securities, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any
character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any Common Shares or the capital stock of any Subsidiary, or
contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to issue additional Common Shares or Common Share Equivalents or capital stock of any Subsidiary. The issuance and sale of the
Securities will not obligate the Company or any Subsidiary to issue Common Shares or other securities to any Person (other than the Purchasers and the Placement Agents) and will not result in a right of any holder of Company securities to adjust the
exercise, conversion, exchange or reset price under any of such securities. Except as set forth in the SEC Reports, there are no outstanding securities or instruments of the Company or any Subsidiary with any provision that adjusts the exercise,
conversion, exchange or reset price of such security or instrument upon an issuance of securities by the Company or any Subsidiary. There are no outstanding securities or instruments of the Company or any Subsidiary that contain any redemption or
similar provisions, and there are no contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to redeem a security of the Company or such Subsidiary. The Company does not have any stock
appreciation rights or &#147;phantom stock&#148; plans or agreements or any similar plan or agreement. All of the outstanding shares of capital stock of the Company are duly authorized, validly issued, fully paid and nonassessable, have been issued
in compliance with all applicable federal and state securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities. Except for the Required Approvals,
no further approval or authorization of any stockholder, the Board of Directors or others is required for the issuance and sale of the Securities. Except as set forth in the SEC Reports, there are no shareholders agreements, voting agreements or
other similar agreements with respect to the Company&#146;s capital stock to which the Company is a party or, to the knowledge of the Company, between or among any of the Company&#146;s shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(h) <U>SEC Reports; Financial Statements</U>. The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the
Company under the Securities Act and Exchange Act, including pursuant to Section&nbsp;13(a) or 15(d) thereof, for the two years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such
materials) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, together with the Prospectus and the Prospectus Supplement, being collectively referred to herein as the &#147;<U>SEC
Reports</U>&#148;) on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their respective dates, the SEC Reports complied in all material
respects with the requirements of the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or
necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The Company has never been an issuer subject to Rule 144(i) under the Securities Act. The financial statements of the
Company included in the SEC Reports complied in all material respects with applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of filing. Such financial statements have
been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis during the periods involved (&#147;<U>GAAP</U>&#148;), except as may be otherwise specified in such financial statements or the
notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company and its consolidated Subsidiaries as of and for the dates
thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, <FONT STYLE="white-space:nowrap">year-end</FONT> audit adjustments. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(i) <U>Material Changes; Undisclosed Events, Liabilities or Developments</U>. Since the date of the latest
audited financial statements included within the SEC Reports, except as set forth in any subsequent SEC Report or on <U>Schedule 3.1(i)</U>, (i) there has been no event, occurrence or development that has had or that could reasonably be expected to
result in a Material Adverse Effect, (ii)&nbsp;the Company has not incurred any liabilities (contingent or otherwise) other than (A)&nbsp;trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice
and (B)&nbsp;liabilities not required to be reflected in the Company&#146;s financial statements pursuant to GAAP or disclosed in filings made with the Commission, (iii)&nbsp;the Company has not altered its method of accounting, (iv)&nbsp;the
Company has not declared or made any dividend or distribution of cash or other property to its shareholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock and (v)&nbsp;the Company has not issued
any equity securities to any officer, director or Affiliate, except pursuant to the Equity Plan. The Company does not have pending before the Commission any request for confidential treatment of information. Except for the issuance of the Securities
contemplated by this Agreement or as set forth on <U>Schedule 3.1(i)</U>, no event, liability, fact, circumstance, occurrence or development has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its
Subsidiaries or their respective businesses, prospects, properties, operations, assets or financial condition that would be required to be disclosed by the Company under applicable securities laws at the time this representation is made or deemed
made that has not been publicly disclosed at least 1 Trading Day prior to the date that this representation is made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(j) <U>Litigation</U>. There is no
action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective properties before or by any court,
arbitrator, governmental or administrative agency or regulatory authority , Canadian, United States or foreign, including any proceeding before Health Canada or any other governmental authority in Canada or any other country performing functions
similar to those performed by Health Canada (collectively, an &#147;<U>Action</U>&#148;) which (i)&nbsp;adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents, the Shares or the Warrant Shares or
(ii)&nbsp;could, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any Subsidiary, nor any director or officer thereof, is or has been the subject of any Action
involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty. There has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by the
Commission involving the Company or any current or former director or officer of the Company. The Commission has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company or any
Subsidiary under the Exchange Act or the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(k) <U>Labor Relations</U>. No labor dispute exists or, to the knowledge of the Company, is
imminent with respect to any of the employees of the Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company&#146;s or its Subsidiaries&#146; employees is a member of a union that relates to such
employee&#146;s relationship with the Company or such Subsidiary, and neither the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe that their relationships with their
employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary, is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary
information agreement or <FONT STYLE="white-space:nowrap">non-competition</FONT> agreement, or any other contract or agreement or any restrictive covenant in favor of any third party, and the continued employment of each such executive officer does
not subject the Company or any of its Subsidiaries to any liability with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all applicable U.S. federal, state, local and foreign laws and regulations
relating to employment and employment practices, terms and conditions of employment and wages and hours, except where the failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(l) <U>Compliance</U>. Neither the Company nor any Subsidiary: (i)&nbsp;is in default under or in violation of (and no event has occurred that
has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in
violation of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived), (ii) is in violation of
any judgment, decree or order of any court, arbitrator or other governmental authority or (iii)&nbsp;is or has been in violation of any statute, rule, ordinance or regulation of any governmental authority, including without limitation all applicable
federal, provincial, territorial, state, municipal, local and foreign laws, regulations, orders and decrees governing its business as prescribed by Health Canada, or any other federal, provincial, territorial, state, municipal, local or foreign
agencies or bodies in Canada or any other country engaged in the regulation of cannabis, controlled drugs and substances or pharmaceuticals, except where noncompliance would not, singularly or in the aggregate, have a Material Adverse Effect. </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(m) <U>Environmental Laws</U>. The Company and its Subsidiaries (i)&nbsp;are in compliance with all
applicable federal, state, local and foreign laws relating to pollution or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface strata), including laws relating to emissions,
discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or hazardous substances or wastes (collectively, &#147;<U>Hazardous Materials</U>&#148;) into the environment, or otherwise relating to the manufacture,
processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters,
orders, permits, plans or regulations, issued, entered, promulgated or approved thereunder (&#147;<U>Environmental Laws</U>&#148;); (ii) have received all permits licenses or other approvals required of them under applicable Environmental Laws to
conduct their respective businesses; and (iii)&nbsp;are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i), (ii) and (iii), the failure to so comply could be reasonably expected to have,
individually or in the aggregate, a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(n) <U>Regulatory Permits</U>. The Company and the Subsidiaries possess all certificates,
authorizations and permits issued by the appropriate federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports, except where the failure to possess such permits could not
reasonably be expected to result in a Material Adverse Effect (&#147;<U>Material Permits</U>&#148;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or modification of any Material Permit.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(o) <U>Title to Assets</U>. Except as set forth in the SEC Reports, the Company and the Subsidiaries have good and marketable title in fee simple to all
real property owned by them and good and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries, in each case free and clear of all Liens, except for (i)&nbsp;Liens as do not
materially affect the value of such property and do not materially interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries, and (ii)&nbsp;Liens for the payment of federal, state or other taxes, for
which appropriate reserves have been made therefor in accordance with GAAP and, the payment of which is neither delinquent nor subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries are held by
them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance, except where the failure to be in compliance would not reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(p) <U>Intellectual Property</U>. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark
applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and similar rights necessary or required for use in connection with their respective businesses as described in the SEC
Reports (collectively, the &#147;<U>Intellectual Property Rights</U>&#148;). None of, and neither the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual Property Rights has expired, terminated or
been abandoned. Neither the Company nor any Subsidiary has received, since the date of the latest audited financial statements included within the SEC Reports, a written notice of a claim or otherwise has any knowledge that the Intellectual Property
Rights violate or infringe upon the rights of any Person, except as could not have or reasonably be expected to not have a Material Adverse Effect. To the knowledge of the Company, all such Intellectual Property Rights are enforceable and there is
no existing infringement by another Person of any of the Intellectual Property Rights. The Company and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and value of all of their intellectual
properties, except where failure to do so could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. The Company has no knowledge of any facts that would preclude it from having valid license rights or
clear title to the Intellectual Property Rights. The Company has no knowledge that it lacks or will be unable to obtain any rights or licenses to use all Intellectual Property Rights that are necessary to conduct its business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(q) <U>Insurance</U>. The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in
such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged. Neither the Company nor any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as
and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant increase in cost. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(r) <U>Transactions With Affiliates and Employees</U>. Except as set forth in the SEC Reports, none of the
officers or directors of the Company or any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party to any transaction with the Company or any Subsidiary (other than for services
as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, providing for the borrowing of money from
or lending of money to or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial interest or is an
officer, director, trustee, stockholder, member or partner, in each case in excess of $120,000 other than for (i)&nbsp;payment of salary or consulting fees for services rendered, (ii)&nbsp;reimbursement for expenses incurred on behalf of the Company
and (iii)&nbsp;other employee benefits, including stock option agreements and restricted share units under the Equity Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(s) <U>Sarbanes-Oxley;
Internal Accounting Controls</U>. The Company and the Subsidiaries are in compliance with any and all applicable requirements of the Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and any and all applicable rules and
regulations promulgated by the Commission thereunder that are effective as of the date hereof and as of the Closing Date. The Company and the Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance
that: (i)&nbsp;transactions are executed in accordance with management&#146;s general or specific authorizations, (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain
asset accountability, (iii)&nbsp;access to assets is permitted only in accordance with management&#146;s general or specific authorization, and (iv)&nbsp;the recorded accountability for assets is compared with the existing assets at reasonable
intervals and appropriate action is taken with respect to any differences. The Company and the Subsidiaries have established disclosure controls and procedures (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT
STYLE="white-space:nowrap">15d-15(e))</FONT> for the Company and the Subsidiaries and designed such disclosure controls and procedures to ensure that information required to be disclosed by the Company in the reports it files or submits under the
Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission&#146;s rules and forms. The Company&#146;s certifying officers have evaluated the effectiveness of the disclosure controls and
procedures of the Company and the Subsidiaries as of the end of the period covered by the most recently filed periodic report under the Exchange Act (such date, the &#147;<U>Evaluation Date</U>&#148;). The Company presented in its most recently
filed periodic report under the Exchange Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have
been no changes in the internal control over financial reporting (as such term is defined in the Exchange Act) of the Company and its Subsidiaries that have materially affected, or is reasonably likely to materially affect, the internal control over
financial reporting of the Company and its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(t) <U>Certain Fees</U>. Except as set forth in the Prospectus or disclosed to the Placement
Agents, no brokerage or finder&#146;s fees or commissions are or will be payable by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to the
transactions contemplated by the Transaction Documents. The Purchasers shall have no obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section that may be
due in connection with the transactions contemplated by the Transaction Documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(u) <U>Investment Company</U>. The Company is not, and is not an
Affiliate of, and immediately after receipt of payment for the Securities, will not be or be an Affiliate of, an &#147;investment company&#148; within the meaning of the Investment Company Act of 1940, as amended. The Company shall conduct its
business in a manner so that it will not become an &#147;investment company&#148; subject to registration under the Investment Company Act of 1940, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(v) <U>Registration Rights</U>. Except as set forth on the SEC Reports, no Person has any right to cause the Company or any Subsidiary to effect the
registration under the Securities Act of any securities of the Company or any Subsidiary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(w) <U>Listing and Maintenance Requirements</U>. The Common
Shares are registered pursuant to Section&nbsp;12(b) or 12(g) of the Exchange Act, and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the Common Shares under
the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating such registration. Except as set forth on the SEC Reports, the Company has not, in the 12 months preceding the date hereof, received
notice from any Trading Market on which the Common Shares are or have been listed or quoted to the effect that the Company is not in compliance with the listing or maintenance requirements of such Trading Market. The Company is, and has no reason to
believe that it will not in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements. The Common Shares are currently eligible for electronic transfer through the Depository Trust Company or another
established clearing corporation and the Company is current in payment of the fees to the Depository Trust Company (or such other established clearing corporation) in connection with such electronic transfer. </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(x) <U>Application of Takeover Protections</U>. The Company and the Board of Directors have taken all
necessary action, if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar anti-takeover provision under the Company&#146;s
articles of incorporation (or similar charter documents) or the laws of its jurisdiction of incorporation that is or could become applicable to the Purchasers as a result of the Purchasers and the Company fulfilling their obligations or exercising
their rights under the applicable Transaction Documents, including without limitation as a result of the Company&#146;s issuance of the Securities and the Purchasers&#146; ownership of the Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(y) <U>Disclosure</U>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company
confirms that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or counsel with any information that it believes constitutes or might constitute material,
<FONT STYLE="white-space:nowrap">non-public</FONT> information which is not otherwise disclosed in the Prospectus Supplement. The Company understands and confirms that the Purchasers will rely on the foregoing representation in effecting
transactions in securities of the Company. All of the disclosure furnished by or on behalf of the Company to the Purchasers regarding the Company and its Subsidiaries, their respective businesses and the transactions contemplated hereby, including
the SEC Reports, is true and correct and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in the light of the circumstances under which they were
made, not misleading. The press releases disseminated by the Company during the twelve months preceding the date of this Agreement taken as a whole do not contain any untrue statement of a material fact or omit to state a material fact required to
be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made and when made, not misleading. The Company acknowledges and agrees that no Purchaser makes or has made any
representations or warranties with respect to the transactions contemplated hereby other than those specifically set forth in Section&nbsp;3.2 hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(z) <U>No Integrated Offering</U>. Assuming the accuracy of the Purchasers&#146; representations and warranties set forth in Section&nbsp;3.2, neither the
Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of
the Securities to be integrated with prior offerings by the Company for purposes of any applicable shareholder approval provisions of any Trading Market on which any of the securities of the Company are listed or designated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(aa) <U>Solvency</U>. Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt by the Company
of the proceeds from the sale of the Securities hereunder, (i)&nbsp;the fair saleable value of the Company&#146;s assets exceeds the amount that will be required to be paid on or in respect of the Company&#146;s existing debts and other liabilities
(including known contingent liabilities) as they mature, (ii)&nbsp;the Company&#146;s assets do not constitute unreasonably small capital to carry on its business as now conducted and as proposed to be conducted including its capital needs taking
into account the particular capital requirements of the business conducted by the Company, consolidated and projected capital requirements and capital availability thereof, and (iii)&nbsp;the current cash flow of the Company, together with the
proceeds the Company would receive, were it to liquidate all of its assets, after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its liabilities when such amounts are required to be
paid. The Company does not intend to incur debts beyond its ability to pay such debts as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its debt). The Company has no knowledge of any facts or
circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from the Closing Date. The SEC Reports sets forth as of the date hereof all
outstanding secured and unsecured Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments. For the purposes of this Agreement, &#147;<U>Indebtedness</U>&#148; means (x)&nbsp;any liabilities for
borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable incurred in the ordinary course of business), (y) all guaranties, endorsements and other contingent obligations in respect of indebtedness of others, whether or
not the same are or should be reflected in the Company&#146;s consolidated balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of
business; and (z)&nbsp;the present value of any lease payments in excess of $50,000 due under leases required to be capitalized in accordance with GAAP. Neither the Company nor any Subsidiary is in default with respect to any Indebtedness. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(bb) <U>Tax Status</U>. Except for matters that would not, individually or in the aggregate, have or
reasonably be expected to result in a Material Adverse Effect, the Company and its Subsidiaries each (i)&nbsp;has made or filed all Canadian, United States federal, state and local income and all foreign income and franchise tax returns, reports and
declarations required by any jurisdiction to which it is subject, (ii)&nbsp;has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports and declarations and
(iii)&nbsp;has set aside on its books provision reasonably adequate for the payment of all material taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material amount
claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no basis for any such claim. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(cc) <U>Foreign Corrupt Practices</U>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent or other
person acting on behalf of the Company or any Subsidiary, has (i)&nbsp;directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity,
(ii)&nbsp;made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii)&nbsp;failed to disclose fully any contribution made by the Company
or any Subsidiary (or made by any person acting on its behalf of which the Company is aware) which is in violation of law, or (iv)&nbsp;violated in any material respect any provision of FCPA or the CFPOA, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(dd) <U>Accountants</U>. The Company&#146;s independent registered public accounting firm is PricewaterhouseCoopers LLP. To the knowledge and belief of the
Company, such accounting firm (i)&nbsp;is a registered public accounting firm as required by the Exchange Act and (ii)&nbsp;shall express its opinion with respect to the financial statements to be included in the Company&#146;s Annual Report for the
fiscal year ended December&nbsp;31, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(ee) <U>Acknowledgment Regarding Purchasers&#146; Purchase of Securities</U>. The Company acknowledges and
agrees that each of the Purchasers is acting solely in the capacity of an arm&#146;s length purchaser with respect to the Transaction Documents and the transactions contemplated thereby. The Company further acknowledges that no Purchaser is acting
as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or any of their respective representatives or
agents in connection with the Transaction Documents and the transactions contemplated thereby is merely incidental to the Purchasers&#146; purchase of the Securities. The Company further represents to each Purchaser that the Company&#146;s decision
to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the transactions contemplated hereby by the Company and its representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(ff) <U>Acknowledgment Regarding Purchaser&#146;s Trading Activity</U>. Anything in this Agreement or elsewhere herein to the contrary notwithstanding (except
for Sections&nbsp;3.2(e) and 4.14 hereof), it is understood and acknowledged by the Company that: (i)&nbsp;none of the Purchasers has been asked by the Company to agree, nor has any Purchaser agreed, to desist from purchasing or selling, long and/or
short, securities of the Company, or &#147;derivative&#148; securities based on securities issued by the Company or to hold the Shares for any specified term; (ii)&nbsp;past or future open market or other transactions by any Purchaser, specifically
including, without limitation, Short Sales or &#147;derivative&#148; transactions, before or after the closing of this or future private placement transactions, may negatively impact the market price of the Company&#146;s publicly-traded securities;
(iii)&nbsp;any Purchaser, and counter-parties in &#147;derivative&#148; transactions to which any such Purchaser is a party, directly or indirectly, presently may have a &#147;short&#148; position in the Common Shares, and (iv)&nbsp;each Purchaser
shall not be deemed to have any affiliation with or control over any arm&#146;s length counter-party in any &#147;derivative&#148; transaction. The Company further understands and acknowledges that (y)&nbsp;one or more Purchasers may engage in
hedging activities (in material compliance with applicable laws) at various times during the period that the Shares are outstanding, and (z)&nbsp;such hedging activities (if any) could reduce the value of the existing stockholders&#146; equity
interests in the Company at and after the time that the hedging activities are being conducted.&nbsp;The Company acknowledges that such aforementioned hedging activities do not constitute a breach of any of the Transaction Documents to which it is a
party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(gg) <U>Regulation M Compliance</U>.&nbsp;The Company has not, and to its knowledge no one acting on its behalf has, (i)&nbsp;taken, directly or
indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of any of the Shares, (ii)&nbsp;sold, bid for, purchased, or, paid any
compensation for soliciting purchases of, any of the Shares, or (iii)&nbsp;paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of the Company, other than, in the case of clauses (ii)&nbsp;and
(iii), compensation paid to the Placement Agents in connection with the placement of the Shares. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(hh) <U>FDA</U>. As to each product subject to the jurisdiction of the U.S. Food and Drug Administration
(&#147;<U>FDA</U>&#148;) under the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (&#147;<U>FDCA</U>&#148;) that is manufactured, packaged, labeled, tested and/or distributed by the Company or any of its Subsidiaries
(each such product, a &#147;<U>Pharmaceutical Product</U>&#148;), such Pharmaceutical Product is being manufactured, packaged, labeled, tested and/or distributed by the Company in compliance with all applicable requirements under FDCA and similar
laws, rules and regulations relating to registration, investigational use, licensure, or application approval, good manufacturing practices, good laboratory practices, good clinical practices, product listing, quotas, labeling, advertising, record
keeping and filing of reports, except where the failure to be in compliance would not have a Material Adverse Effect. There is no pending, completed or, to the Company&#146;s knowledge, threatened, action (including any lawsuit, arbitration, or
legal or administrative or regulatory proceeding, charge, complaint, or investigation) against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice, warning letter or other communication
from the FDA or any other governmental entity, which (i)&nbsp;contests the licensure, registration, or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of
any Pharmaceutical Product, (ii)&nbsp;withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical Product,
(iii)&nbsp;imposes a clinical hold on any clinical investigation by the Company or any of its Subsidiaries, (iv)&nbsp;enjoins production at any facility of the Company or any of its Subsidiaries, (v)&nbsp;enters or proposes to enter into a consent
decree of permanent injunction with the Company or any of its Subsidiaries, or (vi)&nbsp;otherwise alleges any violation of any laws, rules or regulations by the Company or any of its Subsidiaries, and which, either individually or in the aggregate,
would have a Material Adverse Effect. The properties, business and operations of the Company have been and are being conducted in all material respects in accordance with all applicable laws, rules and regulations of the FDA. The Company has not
been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United States of any product produced or marketed by the Company nor has the FDA halted any approved investigational device exemption, clinical program or
other trial of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(ii) <U>Stock Options</U>. Each stock option granted by the Company under the Equity Plan, or as an inducement grant outside
of the Equity Plan, was granted (i)&nbsp;in accordance with the terms of the Equity Plan or under its terms, respectively, and (ii)&nbsp;with an exercise price at least equal to the fair market value of the Common Shares on the date such stock
option would be considered granted under GAAP and applicable law. No stock option granted under the Equity Plan has been backdated. The Company has not knowingly granted, and there is no and has been no Company policy or practice to knowingly grant,
stock options prior to, or otherwise knowingly coordinate the grant of stock options with, the release or other public announcement of material information regarding the Company or its Subsidiaries or their financial results or prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(jj) <U>Office of Foreign Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company&#146;s knowledge, any director, officer, agent,
employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department (&#147;<U>OFAC</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(kk) <U>U.S. Real Property Holding Corporation</U>. The Company is not and has never been a U.S. real property holding corporation within the meaning of
Section&nbsp;897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&#146;s request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(ll) <U>Bank Holding
Company Act</U>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company Act of 1956, as amended (the &#147;<U>BHCA</U>&#148;) and to regulation by the Board of Governors of the Federal Reserve System
(the &#147;<U>Federal Reserve</U>&#148;). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly, five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five
percent or more of the total equity of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries or Affiliates exercises a controlling influence over the management or
policies of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(mm) <U>Money Laundering</U>. The operations of
the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the Proceeds of
Crime (Money Laundering) and Terrorist Financing Act (Canada) and the money laundering statutes of all other applicable jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines issued,
administered or enforced by any governmental agency (collectively, the &#147;<U>Money Laundering Laws</U>&#148;), and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or
any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(nn) <U>Other Covered Persons</U>. Other than the Placement Agents, the Company is not aware of any person
(other than any Issuer Covered Person) that has been or will be paid (directly or indirectly) remuneration for solicitation of purchasers in connection with the sale of any Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(oo) <U>Canadian Reporting Issuer; SEC Registration</U>. The Company is a &#147;reporting issuer&#148; or the equivalent thereof in each of the Canadian
Jurisdictions where such concept exists, is not on the list of defaulting reporting issuers maintained by the Canadian Authorities in each such Canadian Jurisdiction that maintains such a list and is not in breach of any filing requirement under
Canadian Securities Laws which could have a Material Adverse Effect on the Company. The Company is subject to the reporting requirements of Section&nbsp;13 of the Exchange Act and files periodic reports with the SEC; the Common Shares are registered
with the SEC under Section&nbsp;12(b) of the Exchange Act and the Company is not in breach of any filing or other requirements under the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(pp) <U>Cybersecurity</U>. (i)(x) There has been no security breach or other compromise of or relating to any of the Company&#146;s or any Subsidiary&#146;s
information technology and computer systems, networks, hardware, software, data (including the data of its respective customers, employees, suppliers, vendors and any third party data maintained by or on behalf of it), equipment or technology
(collectively, &#147;<U>IT Systems and Data</U>&#148;) and (y)&nbsp;the Company and the Subsidiaries have not been notified of, and has no knowledge of any event or condition that would reasonably be expected to result in, any security breach or
other compromise to its IT Systems and Data; (ii)&nbsp;the Company and the Subsidiaries are presently in material compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or
governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or
modification, except as would not, individually or in the aggregate, have a Material Adverse Effect; (iii)&nbsp;the Company and the Subsidiaries have implemented and maintained commercially reasonable safeguards to maintain and protect its material
confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and Data; and (iv)&nbsp;the Company and the Subsidiaries have implemented backup and disaster recovery technology consistent with
commercially reasonable industry standards and practices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.2 <U>Representations and Warranties of the Purchasers</U>. Each Purchaser, for itself and for
no other Purchaser, hereby represents and warrants as of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case they shall be accurate as of such date): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) <U>Organization; Authority</U>. Such Purchaser is not resident or domiciled in Canada and is either an individual or an entity duly incorporated or
formed, validly existing and in good standing under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability company or similar power and authority to enter into and to consummate the
transactions contemplated by the Transaction Documents to which it is a party and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of the applicable Transaction Documents and performance by such Purchaser
of the transactions contemplated by such Transaction Documents have been duly authorized by all necessary corporate, partnership, limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to
which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof, will constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance
with its terms, except: (i)&nbsp;as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&#146; rights generally,
(ii)&nbsp;as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii)&nbsp;insofar as indemnification and contribution provisions may be limited by applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) <U>Understandings or Arrangements</U>. Such Purchaser is acquiring the Securities as principal for its own account and has no direct or indirect
arrangement or understandings with any other persons to distribute or regarding the distribution of such Shares (this representation and warranty not limiting such Purchaser&#146;s right to sell the Securities pursuant to the Registration Statement
or otherwise in compliance with applicable federal and state securities laws). Such purchaser acknowledges that the Company may be required to file a report of exempt distribution on Form <FONT STYLE="white-space:nowrap">45-106F1</FONT> with certain
of the Canadian Authorities and consents to the Company providing reasonable purchaser information to such Canadian Authorities, where required by applicable law. Such Purchaser is acquiring the Securities hereunder in the ordinary course of its
business. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) <U>Purchaser Status</U>. At the time such Purchaser was offered the Securities, it was, and as of the
date hereof it is, and on each date on which it exercises any Warrants, it will be either (i)&nbsp;an &#147;accredited investor&#148; as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7), (a)(8), (a)(9), (a)(12) or (a)(13) under the Securities Act,
or (ii)&nbsp;a &#147;qualified institutional buyer&#148; as defined in Rule 144A(a) under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) <U>Experience of Such Purchaser</U>.
Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the
Securities, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of an investment in the Securities and, at the present time, is able to afford a complete loss of such investment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(e) <U>Access to Information</U>. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including all exhibits and
schedules thereto) and the SEC Reports and has been afforded, (i)&nbsp;the opportunity to ask such questions as it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the
offering of the Securities and the merits and risks of investing in the Securities; (ii)&nbsp;access to information about the Company and its financial condition, results of operations, business, properties, management and prospects sufficient to
enable it to evaluate its investment; and (iii)&nbsp;the opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary to make an informed investment decision
with respect to the investment.&nbsp;Such Purchaser acknowledges and agrees that neither the Placement Agents nor any Affiliate of the Placement Agents has provided such Purchaser with any information or advice with respect to the Securities nor is
such information or advice necessary or desired.&nbsp;Neither the Placement Agents nor any Affiliate has made or makes any representation as to the Company or the quality of the Securities and the Placement Agents and any Affiliate may have acquired
<FONT STYLE="white-space:nowrap">non-public</FONT> information with respect to the Company which such Purchaser agrees need not be provided to it.&nbsp;In connection with the issuance of the Securities to such Purchaser, neither the Placement Agents
nor any of their Affiliates has acted as a financial advisor or fiduciary to such Purchaser. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(f) <U>Certain Transactions and Confidentiality</U>. Other
than consummating the transactions contemplated hereunder, such Purchaser has not, nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any purchases or sales, including Short
Sales,&nbsp;of the securities of the Company during the period commencing as of the time that such Purchaser first received a term sheet (written or oral) from the Company or any other Person representing the Company setting forth the material terms
of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate
portions of such Purchaser&#146;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser&#146;s assets, the representation set forth above shall
only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Other than to other Persons party to this Agreement or to such Purchaser&#146;s
representatives, including, without limitation, its officers, directors, partners, legal and other advisors, employees, agents and Affiliates, such Purchaser has maintained the confidentiality of all disclosures made to it in connection with this
transaction (including the existence and terms of this transaction). Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty against, or a prohibition of, any actions with
respect to the borrowing of, arrangement to borrow, identification of the availability of, and/or securing of, securities of the Company in order for such Purchaser (or its broker or other financial representative) to effect Short Sales or similar
transactions in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(g) <U>General Solicitation</U>. Such Purchaser is not purchasing the Securities as a result of any advertisement, article,
notice or other communication regarding the Securities published in any newspaper, magazine or similar media or broadcast over television or radio or presented at any seminar or, to the knowledge of such Purchaser, any other general solicitation or
general advertisement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(h) <U>20% Ownership Limitation.</U> In no event will the issuance of any Securities hereunder cause the Purchaser, either alone
or together with any parties that it is acting jointly and in concert with in respect of the Common Shares, to beneficially own or control a number of Common Shares that is equal to or greater than 20% of the issued and outstanding Common Shares (on
a <FONT STYLE="white-space:nowrap">non-diluted</FONT> basis). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company acknowledges and agrees that the representations contained in this Section&nbsp;3.2 shall not
modify, amend or affect such Purchaser&#146;s right to rely on the Company&#146;s representations and warranties contained in this Agreement or any representations and warranties contained in any other Transaction Document or any other document or
instrument executed and/or delivered in connection with this Agreement or the consummation of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation
or warranty, or preclude any actions, with respect to locating or borrowing shares in order to effect Short Sales or similar transactions in the future. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">OTHER
AGREEMENTS OF THE PARTIES </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.1 <U>Legends</U>. The Shares and, if all or any portion of a Warrant is exercised at a time when there is an effective
registration statement to cover the issuance or resale of the Warrant Shares or if the Warrant is exercised via cashless exercise, the Warrant Shares shall be issued free of legends. If at any time following the date hereof the Registration
Statement (or any successor registration statement) is not effective or is not otherwise available for the sale of the Shares, the Warrants or the Warrant Shares, the Company shall immediately notify the holders of the Warrants in writing that such
registration statement is not then effective and thereafter shall promptly notify such holders when a registration statement is effective again and available for the sale of the Shares, the Warrants or the Warrant Shares (it being understood and
agreed that the foregoing shall not limit the ability of the Company to issue, or any Purchaser to sell, any of the Shares, the Warrants or the Warrant Shares in compliance with applicable federal and state securities laws). The Company shall use
commercially reasonable best efforts to keep a registration statement (which may include the Registration Statement) registering the issuance of the Warrant Shares effective during the term of the Warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.2 <U>Furnishing of Information; Public Information</U>. Until the earliest of the time that (i)&nbsp;no Purchaser owns Securities, or (ii)&nbsp;the Common
Warrants have expired, the Company covenants to maintain the registration of the Common Shares under Section&nbsp;12(b) or 12(g) of the Exchange Act and to timely file (or obtain extensions in respect thereof and file within the applicable grace
period) all reports required to be filed by the Company after the date hereof pursuant to the Exchange Act, even if the Company is not then subject to the reporting requirements of the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.3 <U>Integration</U>. The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in
Section&nbsp;2 of the Securities Act) that would be integrated with the offer or sale of the Shares in a manner that would be integrated with the offer or sale of the Shares for purposes of the rules and regulations of any Trading Market such that
it would require shareholder approval prior to the closing of such other transaction unless shareholder approval is obtained before the closing of such subsequent transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.4 <U>Securities Laws Disclosure; Publicity</U>. The Company shall (a)&nbsp;by the Disclosure Time issue a press release disclosing the material terms of the
transactions contemplated hereby, and (b)&nbsp;file a Current Report on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> including the Transaction Documents (or a form thereof) as exhibits thereto, with the Commission within the time required by
the Exchange Act. From and after the issuance of such press release, the Company represents to the Purchasers that it shall have publicly disclosed all material, <FONT STYLE="white-space:nowrap">non-public</FONT> information delivered to any of the
Purchasers by the Company or any of its Subsidiaries, or any of their respective officers, directors, employees or agents in connection with the transactions contemplated by the Transaction Documents. In addition, effective upon the issuance of such
press release, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors,
agents, employees or Affiliates on the one hand, and any of the Purchasers or any of their Affiliates on the other hand, shall terminate. The Company and each Purchaser shall consult with each other in issuing any other press releases with respect
to the transactions contemplated hereby, and neither the Company nor any Purchaser shall issue any such press release nor otherwise make any such public statement without the prior consent of the Company, with respect to any press release of any
Purchaser, or without the prior consent of each Purchaser, with respect to any press release of the Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure is required by law, in which case the disclosing
party shall promptly provide the other party with prior notice of such public statement or communication. Notwithstanding the foregoing, the Company shall not publicly disclose the name of any Purchaser, or include the name of any Purchaser in any
filing with the Commission or any regulatory agency or Trading Market, without the prior written consent of such Purchaser, except (a)&nbsp;as required by federal securities law in connection with the filing of Transaction Documents (or a form
thereof) with the Commission and (b)&nbsp;to the extent such disclosure is required by law or Trading Market regulations, in which case the Company shall provide the Purchasers with prior notice of such disclosure permitted under this clause (b).
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.5 <U>Shareholder Rights Plan</U>. No claim will be made or enforced by the Company or, with the consent of
the Company, any other Person, that any Purchaser is an &#147;<U>Acquiring Person</U>&#148; under any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or similar anti-takeover plan or
arrangement in effect or hereafter adopted by the Company, or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving Shares under the Transaction Documents or under any other agreement
between the Company and the Purchasers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.6 <U><FONT STYLE="white-space:nowrap">Non-Public</FONT> Information</U>. Except with respect to the material
terms and conditions of the transactions contemplated by the Transaction Documents, which shall be disclosed pursuant to Section&nbsp;4.4, the Company covenants and agrees that neither it, nor any other Person acting on its behalf will provide any
Purchaser or its agents or counsel with any information that constitutes, or the Company reasonably believes constitutes, material <FONT STYLE="white-space:nowrap">non-public</FONT> information, unless prior thereto such Purchaser shall have
consented to the receipt of such information and agreed with the Company to keep such information confidential. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in
securities of the Company. To the extent that the Company delivers any material, <FONT STYLE="white-space:nowrap">non-public</FONT> information to a Purchaser without such Purchaser&#146;s consent, the Company hereby covenants and agrees that such
Purchaser shall not have any duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates, or a duty to the Company, any of its Subsidiaries or any of their
respective officers, directors, agents, employees or Affiliates not to trade on the basis of, such material, <FONT STYLE="white-space:nowrap">non-public</FONT> information, provided that the Purchaser shall remain subject to applicable law. To the
extent that any notice provided pursuant to any Transaction Document constitutes, or contains, material, <FONT STYLE="white-space:nowrap">non-public</FONT> information regarding the Company or any Subsidiaries, the Company shall file such material <FONT
STYLE="white-space:nowrap">non-public</FONT> information with the Commission pursuant to a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> as soon as practicable thereafter. The Company understands and confirms that each Purchaser
shall be relying on the foregoing covenant in effecting transactions in securities of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.7 <U>Use of Proceeds</U>. Except as set forth in the
Prospectus Supplement, the Company shall use the net proceeds from the sale of the Securities hereunder for working capital purposes and shall not use such proceeds in violation of FCPA or OFAC regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.8 <U>Indemnification of Purchasers</U>. Subject to the provisions of this Section&nbsp;4.8, the Company will indemnify and hold each Purchaser and its
directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls
such Purchaser (within the meaning of Section&nbsp;15 of the Securities Act and Section&nbsp;20 of the Exchange Act), and the directors, officers, shareholders, agents, members, partners or employees (and any other Persons with a functionally
equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title) of such controlling persons (each, a &#147;<U>Purchaser Party</U>&#148;) harmless from any and all losses, liabilities, obligations, claims,
contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and reasonable attorneys&#146; fees and costs of investigation that any such Purchaser Party may suffer or incur as a result of or relating
to (a)&nbsp;any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement or in the other Transaction Documents to which it is a party or (b)&nbsp;any action instituted against the Purchaser
Parties in any capacity, or any of them or their respective Affiliates, by any shareholder of the Company who is not an Affiliate of such Purchaser Party, with respect to any of the transactions contemplated by the Transaction Documents (unless such
action is solely based upon a material breach of such Purchaser Party&#146;s representations, warranties or covenants under the Transaction Documents or any agreements or understandings such Purchaser Party may have with any such stockholder or any
violations by such Purchaser Party of state or federal securities laws or any conduct by such Purchaser Party which is finally judicially determined to constitute fraud, gross negligence or willful misconduct), the Company will indemnify each
Purchaser Party, to the fullest extent permitted by applicable law, from and against any and all losses, claims, damages, liabilities, costs (including, without limitation, reasonable attorneys&#146; fees) and expenses, as incurred, arising out of
or relating to (i)&nbsp;any untrue or alleged untrue statement of a material fact contained in such registration statement, any prospectus or any form of prospectus or in any amendment or supplement thereto or in any preliminary prospectus, or
arising out of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any prospectus or supplement thereto, in the light of the circumstances under
which they were made) not misleading, except to the extent, but only to the extent, that such untrue statements or omissions are based solely upon information regarding such Purchaser Party furnished in writing to the Company by such Purchaser Party
expressly for use therein, or (ii)&nbsp;any violation or alleged violation by the Company of the Securities Act, the Exchange Act or any state securities law, or any rule or regulation thereunder in connection therewith. If any
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
action shall be brought against any Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly notify the Company in writing, and
the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party shall have the right to employ separate counsel in any such action and participate in
the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Purchaser Party except to the extent that (x)&nbsp;the employment thereof has been specifically authorized by the Company in writing, (y)&nbsp;the Company
has failed after a reasonable period of time to assume such defense and to employ counsel or (z)&nbsp;in such action there is, in the reasonable opinion of counsel, a material conflict on any material issue between the position of the Company and
the position of such Purchaser Party, in which case the Company shall be responsible for the reasonable fees and expenses of no more than one such separate counsel. The Company will not be liable to any Purchaser Party under this Agreement
(1)&nbsp;for any settlement by a Purchaser Party effected without the Company&#146;s prior written consent, which shall not be unreasonably withheld or delayed; or (2)&nbsp;to the extent, but only to the extent that a loss, claim, damage or
liability is attributable to any Purchaser Party&#146;s breach of any of the representations, warranties, covenants or agreements made by such Purchaser Party in this Agreement or in the other Transaction Documents. The indemnification required by
this Section&nbsp;4.8 shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as and when bills are received or are incurred. The indemnity agreements contained herein shall be in addition to any
cause of action or similar right of any Purchaser Party against the Company or others and any liabilities the Company may be subject to pursuant to law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.9 <U>Reservation of Common Shares</U>. The Company shall continue to reserve and keep available at all times, free of preemptive rights, a sufficient number
of Common Shares for the purpose of enabling the Company to issue Shares pursuant to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.10 <U>Listing of Common Shares</U>. The Company
shall notify the Nasdaq of the offering of the Securities to the extent required by the rules of the Nasdaq. The Company further agrees, if the Company applies to have the Common Shares traded on any other Trading Market, it will then include in
such application all of the Shares and Warrant Shares, and will take such other action as is necessary to cause all of the Shares and Warrant Shares to be listed or quoted on such other Trading Market as promptly as possible. The Company will then
use commercially reasonable best efforts to continue the listing and trading of its Common Shares on a Trading Market and will comply in all respects with the Company&#146;s reporting, filing and other obligations under the bylaws or rules of the
Trading Market. For so long as the Company maintains a listing or quotation of the Common Shares on a Trading Market, the Company agrees to maintain the eligibility of the Common Shares for electronic transfer through the Depository Trust Company or
another established clearing corporation, including, without limitation, by timely payment of fees to the Depository Trust Company or such other established clearing corporation in connection with such electronic transfer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.11 <U>[Reserved]</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.12 <U>Subsequent Equity Sales</U>.
From the date hereof until 90 days after the Closing Date, neither the Company nor any Subsidiary shall issue, enter into any agreement to issue or announce the issuance or proposed issuance of any Common Shares or Common Share Equivalents, except
for any Exempt Issuance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.13 <U>Equal Treatment of Purchasers</U>. No consideration (including any modification of any Transaction Document) shall be
offered or paid to any Person to amend or consent to a waiver or modification of any provision of the Transaction Documents unless the same consideration is also offered to all of the parties to such Transaction Documents. For clarification
purposes, this provision constitutes a separate right granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers as a class and shall not in any way be construed as
the Purchasers acting in concert or as a group with respect to the purchase, disposition or voting of Shares or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.14 <U>Certain Transactions
and Confidentiality</U>. Each Purchaser, severally and not jointly with the other Purchasers, covenants that neither it nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including
Short Sales of any of the Company&#146;s securities during the period commencing with the execution of this Agreement and ending at such time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial
press release as described in Section&nbsp;4.4.&nbsp;Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time as the transactions contemplated by this Agreement are publicly disclosed by the Company
pursuant to the initial press release as described in Section&nbsp;4.4, such Purchaser will maintain the confidentiality of the existence and terms of this transaction and the information included in the Disclosure Schedules.&nbsp;Notwithstanding
the foregoing, and notwithstanding anything contained in this Agreement to </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the contrary, the Company expressly acknowledges and agrees that (i)&nbsp;no Purchaser makes any representation, warranty or covenant hereby that it will not engage in effecting transactions in
any securities of the Company after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section&nbsp;4.4, (ii) no Purchaser shall be restricted or
prohibited from effecting any transactions in any securities of the Company in accordance with applicable securities laws from and after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the
initial press release as described in Section&nbsp;4.4 and (iii)&nbsp;no Purchaser shall have any duty of confidentiality or duty not to trade in the securities of the Company to the Company or its Subsidiaries after the issuance of the initial
press release as described in Section&nbsp;4.4.&nbsp;Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&#146;s assets
and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser&#146;s assets, the covenant set forth above shall only apply with respect to the portion of
assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.15 <U>Exercise
Procedures</U>. The form of Notice of Exercise included in the Warrants sets forth the totality of the procedures required of the Purchasers in order to exercise the Warrants. To the Company&#146;s knowledge, no additional legal opinion, other
information or instructions shall be required of the Purchasers by the Transfer Agent to exercise their Warrants. Without limiting the preceding sentences, no <FONT STYLE="white-space:nowrap">ink-original</FONT> Notice of Exercise shall be required,
nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required by the Company in order to exercise the Warrants. The Company shall honor exercises of the Warrants and shall deliver Warrant
Shares in accordance with the terms, conditions and time periods set forth in the Transaction Documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.16 <U>Reservations of Shares</U>. As of the
date hereof, the Company has reserved and the Company shall continue to reserve and keep available at all times, free of preemptive rights, a sufficient number of Common Shares for the purpose of enabling the Company to issue Common Shares pursuant
to this Agreement and Warrant Shares pursuant to any exercise of the Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.17 <U><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements</U>.
The Company shall not amend, modify, waive or terminate any provision of any of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements without the prior written consent of the Placement Agents, except to extend the term of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> period, and shall enforce the provisions of each <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement in accordance with its terms. If any party to a <FONT STYLE="white-space:nowrap">Lock-Up</FONT>
Agreement breaches any provision of a <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, the Company shall promptly use its best efforts to seek specific performance of the terms of such <FONT STYLE="white-space:nowrap">Lock-Up</FONT>
Agreement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE V. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MISCELLANEOUS </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.1 <U>Termination</U>.&nbsp;This
Agreement may be terminated by any Purchaser, as to such Purchaser&#146;s obligations hereunder only and without any effect whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the
Closing has not been consummated on or before the fifth (5th) Trading Day following the date hereof; <U>provided</U>, <U>however</U>, that no such termination will affect the right of any party to sue for any breach by any other party (or parties).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.2 <U>Fees and Expenses</U>. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and expenses of
its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent
fees (including, without limitation, any fees required for <FONT STYLE="white-space:nowrap">same-day</FONT> processing of any instruction letter delivered by the Company and any exercise notice delivered by a Purchaser), stamp taxes and other taxes
and duties levied in connection with the delivery of any Shares to the Purchasers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.3 <U>Entire Agreement</U>. The Transaction Documents, together with
the exhibits and schedules thereto, contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the
parties acknowledge have been merged into such documents, exhibits and schedules. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.4 <U>Notices</U>. Any and all notices or other communications or deliveries required or permitted to be
provided hereunder shall be in writing and shall be deemed given and effective on the earliest of: (a)&nbsp;the time of transmission, if such notice or communication is delivered via facsimile at the facsimile number or email attachment at the email
address as set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New York City time) on a Trading Day, (b)&nbsp;the next Trading Day after the time of transmission, if such notice or communication is delivered via facsimile at
the facsimile number or email attachment at the email address as set forth on the signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (c)&nbsp;the second (2nd)Trading
Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service or (d)&nbsp;upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as
set forth on the signature pages attached hereto. To the extent that any notice provided pursuant to any Transaction Document constitutes, or contains, material, <FONT STYLE="white-space:nowrap">non-public</FONT> information regarding the Company or
any Subsidiaries, the Company shall file such notice with the Commission pursuant to a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> as soon as practicable thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.5 <U>Amendments; Waivers</U>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in the
case of an amendment, by the Company and all of the Purchasers in the event of an amendment prior to the Closing Date, and subsequent to the Closing date the Purchasers which purchased at least a majority in interest of the Shares based on the
initial Subscription Amounts hereunder or, in the case of a waiver, by the party against whom enforcement of any such waived provision is sought, provided that if any amendment, modification or waiver disproportionately and adversely impacts a
Purchaser (or group of Purchasers), the consent of such disproportionately impacted Purchaser (or group of Purchasers) shall also be required. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall
be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner
impair the exercise of any such right. Any proposed amendment or waiver that disproportionately, materially and adversely affects the rights and obligations of any Purchaser relative to the comparable rights and obligations of the other Purchasers
shall require the prior written consent of such adversely affected Purchaser. Any amendment effected in accordance with this Section&nbsp;5.5 shall be binding upon each Purchaser and the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.6 <U>Headings</U>. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any
of the provisions hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.7 <U>Successors and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their
successors and permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of each Purchaser (other than by merger). Any Purchaser may assign any or all of its rights under
this Agreement to any Person to whom such Purchaser assigns or transfers any Shares, provided that such transferee agrees in writing to be bound, with respect to the transferred Shares, by the provisions of the Transaction Documents that apply to
the &#147;Purchasers.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.8 <U>No Third-Party Beneficiaries</U>. The Placement Agents shall be the third party beneficiary of the representations and
warranties of the Company in Section&nbsp;3.1 and the representations and warranties of the Purchasers in Section&nbsp;3.2. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is
not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in Section&nbsp;4.8 and this Section&nbsp;5.8. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.9 <U>Governing Law</U>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be governed
by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and
defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be
commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the
adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and
agrees not to assert in any action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such action or proceeding is improper or is an inconvenient venue for such Proceeding. Each party hereby
irrevocably waives personal service of process and consents to process being served in any such action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the
address in effect for notices to it under this Agreement and agrees that such service shall constitute </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If any
party shall commence an action or proceeding to enforce any provisions of the Transaction Documents, then, in addition to the obligations of the Company under Section&nbsp;4.8, the prevailing party in such action or proceeding shall be reimbursed by
the non-prevailing party for its reasonable attorneys&#146; fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.10 <U>Survival</U>. The representations and warranties contained herein shall survive the Closing for a period of five (5)&nbsp;years from the Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.11 <U>Execution</U>. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same
agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by
facsimile transmission or by <FONT STYLE="white-space:nowrap">e-mail</FONT> delivery of a &#147;.pdf&#148; format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is
executed) with the same force and effect as if such facsimile or &#147;.pdf&#148; signature page were an original thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.12 <U>Severability</U>. If
any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall
remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same
result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without
including any of such that may be hereafter declared invalid, illegal, void or unenforceable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.13 <U>Rescission and Withdrawal Right</U>.
Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document and the
Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or
election in whole or in part without prejudice to its future actions and rights; provided, however, that, in the case of a rescission of an exercise of a Warrant in accordance with the terms thereof, the applicable Purchaser shall be required to
return any Common Shares subject to any such rescinded exercise notice concurrently with the return to such Purchaser of the aggregate exercise price paid to the Company for such Common Shares and the restoration of such Purchaser&#146;s right to
acquire such Common Shares pursuant to such Purchaser&#146;s Warrant (including, issuance of a replacement warrant certificate evidencing such restored right). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.14 <U>Replacement of Securities</U>. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company shall
issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably
satisfactory to the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also pay any reasonable third-party costs (including customary indemnity) associated with the issuance
of such replacement Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.15 <U>Remedies</U>. In addition to being entitled to exercise all rights provided herein or granted by law, including
recovery of damages, each of the Purchasers and the Company will be entitled to seek specific performance under the Transaction Documents. The parties agree that monetary damages may not be adequate compensation for any loss incurred by reason of
any breach of obligations contained in the Transaction Documents and hereby agree to waive and not to assert in any action for specific performance of any such obligation the defense that a remedy at law would be adequate. Each party agrees that it
shall not have a remedy of punitive or consequential damages against the other and hereby waives any right or claim to punitive or consequential damages it may now have or may arise in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.16 <U>Payment Set Aside</U>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document or a Purchaser
enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from,
disgorged by or are required to be refunded, repaid or otherwise </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
restored to the Company, a trustee, receiver or any other Person under any law (including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action),
then to the extent of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not been made or such enforcement or setoff had not
occurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.17 <U>Independent Nature of Purchasers&#146; Obligations and Rights</U>. The obligations of each Purchaser under any Transaction Document are
several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or <FONT STYLE="white-space:nowrap">non-performance</FONT> of the obligations of any other Purchaser under any
Transaction Document. Nothing contained herein or in any other Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as a partnership, an association, a joint venture or
any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Purchaser shall be entitled to
independently protect and enforce its rights including, without limitation, the rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party
in any proceeding for such purpose. Each Purchaser has been represented by its own separate legal counsel in its review and negotiation of the Transaction Documents. For reasons of administrative convenience only, each Purchaser and its respective
counsel have chosen to communicate with the Company through the legal counsel of the Placement Agents. The legal counsel of the Placement Agents does not represent any of the Purchasers and only represents the Placement Agents. The Company has
elected to provide all Purchasers with the same terms and Transaction Documents for the convenience of the Company and not because it was required or requested to do so by any of the Purchasers. It is expressly understood and agreed that each
provision contained in this Agreement and in each other Transaction Document is between the Company and a Purchaser, solely, and not between the Company and the Purchasers collectively and not between and among the Purchasers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.18 <U>[Reserved]</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.19 <U>Saturdays, Sundays, Holidays,
etc.</U> If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business
Day. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.20 <U>Construction</U>. The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the
Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments
thereto. In addition, each and every reference to share prices and Common Shares in any Transaction Document shall be subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of
the Common Shares that occur after the date of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.21 <B><U>WAIVER OF JURY TRIAL</U></B><B>. </B><B><U>IN ANY ACTION, SUIT, OR PROCEEDING
IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY
JURY. </U></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Signature Pages Follow) </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by
their respective authorized signatories as of the date first indicated above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">VILLAGE FARMS INTERNATIONAL, INC.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><U>Address for Notice:</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Fax:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">E-mail:</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK SIGNATURE PAGE FOR PURCHASER FOLLOWS] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[PURCHASER SIGNATURE PAGES TO VFF SECURITIES PURCHASE AGREEMENT] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the
date first indicated above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name of Purchaser: ______________________________________________________ </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Signature of Authorized Signatory of Purchaser</I>: _________________________________ </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name of Authorized Signatory: _______________________________________________ </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title of Authorized Signatory: ________________________________________________ </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email Address of Authorized Signatory:_________________________________________ </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Facsimile Number of Authorized Signatory: __________________________________________ </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Address for Notice to Purchaser: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Address for Delivery of
Warrant Shares to the Purchaser (if not same address for notice): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DWAC for Shares: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subscription Amount: $_________________ </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shares:
_________________ </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Warrant Shares underlying the Common Warrants: ________ </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beneficial Ownership Blocker &#9744; 4.99% or &#9744; 9.99% </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EIN Number: ____________________ </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#9744; Notwithstanding
anything contained in this Agreement to the contrary, by checking this box (i)&nbsp;the obligations of the above-signed to purchase the securities set forth in this Agreement to be purchased from the Company by the above-signed, and the obligations
of the Company to sell such securities to the above-signed, shall be unconditional and all conditions to Closing shall be disregarded, (ii)&nbsp;the Closing shall occur on the second (2nd) Trading Day following the date of this Agreement and
(iii)&nbsp;any condition to Closing contemplated by this Agreement (but prior to being disregarded by clause (i)&nbsp;above) that required delivery by the Company or the above-signed of any agreement, instrument, certificate or the like or purchase
price (as applicable) shall no longer be a condition and shall instead be an unconditional obligation of the Company or the above-signed (as applicable) to deliver such agreement, instrument, certificate or the like or purchase price (as applicable)
to such other party on the Closing Date. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit A </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of Common Warrant </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(See
Attached) </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit B </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(See Attached) </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>6
<FILENAME>d369529dex102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">January [&#149;], 2023 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A.G.P./Alliance Global
Partners </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">590 Madison Avenue, 28th Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York
10022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cantor Fitzgerald&nbsp;&amp; Co. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">110 East 59th
Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement (this &#147;<B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement</B>&#148;) is being
delivered to you in connection with the offering (the &#147;<B>Offering</B>&#148;) contemplated by those certain Securities Purchase Agreements (each, a &#147;<B>Purchase Agreement</B>&#148; and collectively, the &#147;<B>Purchase
Agreements</B>&#148;), each dated as of January [&#149;], 2023, between Village Farms International, Inc. (the &#147;<B>Company</B>&#148;) and the purchaser parties thereto (collectively, the &#147;<B>Purchasers</B>&#148;), with respect to the
issuance of (i)&nbsp;common shares of the Company, no par value (&#147;<B>Common Shares</B>&#148;) and (ii)&nbsp;warrants to purchase Common Shares (the &#147;<B>Warrants</B>&#148;), which Warrants will be exercisable into Common Shares. Capitalized
terms used herein and not otherwise defined shall have the respective meanings set forth in the Purchase Agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To induce the Purchasers enter into
the Purchase Agreement, the undersigned hereby agrees that, without the prior written consent of the Placement Agents, the undersigned will not, and will cause all affiliates (as defined in Rule 144 promulgated under the Securities Act) of the
undersigned or any person in privity with the undersigned not to, during the period commencing on the date hereof and ending 90 days after the Closing Date (the &#147;<B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period</B>&#148;),
(1)&nbsp;offer, pledge, sell, contract to sell, encumber, grant, lend, or otherwise transfer or dispose of, directly or indirectly, any Securities or any securities convertible into or exercisable or exchangeable for Common Shares, whether now owned
or hereafter acquired by the undersigned or with respect to which the undersigned has or hereafter acquires the power of disposition (collectively, the &#147;<B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities</B>&#148;); (2)&nbsp;enter
into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, whether any such transaction described in clause
(1)&nbsp;or (2)&nbsp;above is to be settled by delivery of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, in cash or otherwise; (3)&nbsp;make any demand for or exercise any right with respect to the registration of any <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Securities; or (4)&nbsp;publicly disclose the intention to make any offer, sale, pledge or disposition of, or to enter into any transaction, swap, hedge or other arrangement relating to, any <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Securities. Notwithstanding the foregoing, and subject to the conditions below, the undersigned may transfer <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities without the prior written consent of
the Placement Agent in connection with (a)&nbsp;transactions relating to <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities acquired in open market transactions after the completion of the Offering; <I>provided</I> that no filing under
Section&nbsp;16(a)&nbsp;of the Exchange Act, shall be voluntarily made in connection with subsequent sales of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities acquired in such open market transactions; (b)&nbsp;transfers of <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Securities as a <I>bona</I><I></I><I>&nbsp;fide</I> gift, by will or intestacy, pursuant to a qualified domestic relations order or in connection with a divorce settlement or to a family member or trust for
the benefit of a family member (for purposes of this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, &#147;family member&#148; means any relationship by blood, marriage or adoption, not more remote than first cousin); (c)&nbsp;transfers
of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities to a charity or educational institution; (d)&nbsp;if the undersigned, directly or indirectly, controls a corporation, partnership, limited liability company or other business entity, any
transfers of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities to any shareholder, partner or member of, or owner of similar equity interests in, the undersigned, as the case may be; (e)&nbsp;transfer of
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities in order to make payments of taxes then due (including, but not limited to, any &#147;net&#148; or &#147;cashless&#148; exercise or settlement of options or warrants); (f) the sale of Common
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Shares pursuant to a <FONT STYLE="white-space:nowrap">&#147;10b5-1&#148;</FONT> trading plan that is in existence as of the date hereof; (g)&nbsp;any deemed disposition in connection with any
vesting or exercise by the undersigned of any option or warrant, outstanding as of the date hereof, to acquire any Common Shares or upon vesting of any restricted shares or restricted share units under the Company&#146;s Amended and Restated
Share-Based Compensation Plan, dated March&nbsp;15, 2021 and adopted June&nbsp;10, 2021; or (h)&nbsp;transfers of Common Shares or other <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities in connection with the conversion, reclassification,
exchange or swap of any outstanding preferred shares, other classes of common equity or other <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities into shares of one or more series or classes of Common Shares or
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, provided that any such Common Shares or <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities received upon such conversion, reclassification, exchange or swap shall be subject to the
terms of this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement; <I>provided</I> that in the case of any transfer pursuant to the foregoing clauses (b), (c), (d), (e), (g) or (h), (i)&nbsp;any such transfer shall not involve a disposition
for value, (ii)&nbsp;each transferee shall sign and deliver to the Placement Agent a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement substantially in the form of this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement and
(iii)&nbsp;no filing under Section&nbsp;16(a)&nbsp;of the Exchange Act shall be voluntarily made. The undersigned also agrees and consents to the entry of stop transfer instructions with the Company&#146;s transfer agent and registrar against the
transfer of the undersigned&#146;s <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities except in compliance with this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the undersigned is an officer or director of the Company, (i)&nbsp;the undersigned agrees that the foregoing restrictions shall be equally applicable to
any issuer-directed or &#147;friends and family&#148; Securities that the undersigned may purchase in the Offering; and (ii)&nbsp;the Placement Agent agrees that, at least three business days before the effective date of any release or waiver of the
foregoing restrictions in connection with a transfer of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, the Placement Agent will notify the Company of the impending release or waiver. The provisions of this paragraph will not apply if
(a)&nbsp;the release or waiver is effected solely to permit a transfer of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities not for consideration and (b)&nbsp;the transferee has agreed in writing to be bound by the same terms described in
this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement to the extent and for the duration that such terms remain in effect at the time of such transfer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No provision in this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement shall be deemed to restrict or prohibit the exercise, exchange or conversion by
the undersigned of any securities exercisable or exchangeable for or convertible into Common Shares, as applicable; <I>provided</I> that the undersigned does not transfer the Common Shares acquired on such exercise, exchange or conversion during the
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period, unless otherwise permitted pursuant to the terms of this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement. In addition, no provision herein shall be deemed to restrict or prohibit the
entry into or modification of a <FONT STYLE="white-space:nowrap">so-called</FONT> <FONT STYLE="white-space:nowrap">&#147;10b5-1&#148;</FONT> plan at any time (other than the entry into or modification of such a plan in such a manner as to cause the
sale of any <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities within the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
undersigned understands that the Company, the Purchasers and the Placement Agent are relying upon this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement in proceeding toward consummation of the Offering. The undersigned further understands
that this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement is irrevocable and shall be binding upon the undersigned&#146;s heirs, legal representatives, successors and assigns.&nbsp;This <FONT STYLE="white-space:nowrap">Lock-Up</FONT>
Agreement may not be amended without the prior written consent of the Purchasers and the Placement Agents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned understands that, if the
Purchase Agreement is not executed by January&nbsp;31, 2023, or if the Purchase Agreement (other than the provisions thereof which survive termination) terminates prior to the initial closing date of the Securities to be sold thereunder, then this <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Agreement shall be void and of no further force or effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This <FONT STYLE="white-space:nowrap">Lock-Up</FONT>
Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provisions hereof be enforced by, any other person. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[Remainder of Page&nbsp;Intentionally Blank] </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whether or not the Offering actually occurs depends on a number of factors, including market conditions. Any
Offering will only be made pursuant to the Purchase Agreement, the terms of which are subject to negotiation between the Company, the Purchasers and the Placement Agents. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">(Name&#151;Please Print)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">(Signature)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(Name of Signatory, in the case of entities&#151; Please Print)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(Title of Signatory, in the case of entities&#151; Please Print)</TD></TR></TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Address:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>7
<FILENAME>d369529dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Village Farms International Completes Approximately US$25 Million Registered Direct Offering </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">VANCOUVER, BC, Jan. 30, 2023 /PRNewswire/&#151;Village Farms International, Inc. (&#147;Village Farms&#148; or the &#147;Company&#148;) (NASDAQ: VFF) today
announced it has completed its previously announced registered direct offering with certain institutional investors for the purchase and sale of an aggregate of 18,350,000 common shares at US$1.35 per share, together with accompanying warrants to
purchase up to 18,350,000 common shares, which have an exercise price of US$1.65 per share (the &#147;Offering&#148;). The proceeds from the sale of the common shares are approximately US$25&nbsp;million, before deducting placement agent fees and
other offering expenses payable by Village Farms. The warrants will be exercisable beginning on July&nbsp;30, 2023 and will expire on July&nbsp;30, 2028. Proceeds from the exercise of all the warrants would be approximately US$30&nbsp;million over
this period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The net proceeds from this Offering are intended to be used for general working capital purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon closing of the Offering, there were 110,238,929 issued and outstanding common shares of Village Farms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A.G.P./Alliance Global Partners and Cantor Fitzgerald&nbsp;&amp; Co. acted as <FONT STYLE="white-space:nowrap">co-lead</FONT> placement agents for the
Offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities
in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Updated Early Warning Disclosure </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of the
Offering, Michael DeGiglio&#146;s (founder, President, Chief Executive Officer and Director of Village Farms) ownership of Village Farms was diluted below 10% of Village Farms&#146; issued and outstanding common shares. Immediately prior to closing
of the Offering, Mr.&nbsp;DeGiglio beneficially owned 9,259,529 common shares of Village Farms and vested stock options exercisable for 1,180,722 common shares of Village Farms, collectively representing approximately 11.4% of the issued and
outstanding common shares of Village Farms (assuming the exercise of the vested stock options). Mr.&nbsp;DeGiglio did not participate in the Offering. Immediately following closing of the Offering, Mr.&nbsp;DeGiglio continues to beneficially own
9,259,529 common shares of Village Farms and vested stock options exercisable for 1,180,722 common shares of Village Farms, collectively representing approximately 9.4% of the issued and outstanding common shares of Village Farms (assuming the
exercise of the vested stock options). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because Mr.&nbsp;DeGiglio now owns or exercises control or direction over less than 10% of the issued and
outstanding common shares of Village Farms, Mr.&nbsp;DeGiglio is no longer subject to ongoing early warning reporting requirements under applicable Canadian securities laws in respect of his ownership of Village Farms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the future, Mr.&nbsp;DeGiglio may from time to time dispose or acquire ownership of, or control or direction over, additional common shares of Village
Farms for investment purposes. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An early warning report with additional information in respect of the foregoing matter has been filed and is
available on the issuer profile of Village Farms at www.sedar.com. To obtain a copy of the early warning report, please visit https://villagefarms.com/investor-relations/information-request-form and provide your name and physical address, or contact
Lawrence Chamberlain, Investor Relations, at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">416-519-4196.</FONT></FONT> Village Farms&#146; head office is located at 4700&#151;80th Street, Delta, British Columbia, V4K 3N3. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Village Farms International, Inc. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Village Farms
leverages decades of experience as a large-scale, Controlled Environment Agriculture-based, vertically integrated supplier for high-value, high-growth plant-based Consumer Packaged Goods opportunities, with a strong foundation as a leading fresh
produce supplier to grocery and large-format retailers throughout the US and Canada, and new high-growth opportunities in the cannabis and CBD categories in North America and selected markets internationally. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In Canada, the Company&#146;s wholly-owned Canadian subsidiary, Pure Sunfarms, is one of the single largest cannabis operations in the world, the lowest-cost
greenhouse producer and one of Canada&#146;s best-selling brands. The Company also owns 70% of <FONT STYLE="white-space:nowrap">Qu&eacute;bec-based,</FONT> Rose LifeScience, a leading third-party cannabis products commercialization expert in the
Province of Qu&eacute;bec. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the US, wholly-owned Balanced Health Botanicals is one of the leading CBD brands and
<FONT STYLE="white-space:nowrap">e-commerce</FONT> platforms in the country. Subject to compliance with all applicable US federal and state laws and stock exchange rules, Village Farms plans to enter the US
<FONT STYLE="white-space:nowrap">high-THC</FONT> cannabis market via multiple strategies, leveraging one of the largest greenhouse operations in the country (more than 5.5&nbsp;million square feet in West Texas), as well as the operational and
product expertise gained through Pure Sunfarms&#146; cannabis success in Canada. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Internationally, Village Farms is targeting selected, nascent, legal
cannabis and CBD opportunities with significant medium- and long-term potential, with an initial focus on the Asia-Pacific region, Israel and Europe. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cautionary Statement Regarding Forward-Looking Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995,
Section&nbsp;27A of the U.S. Securities Act of 1933, as amended, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, and is subject to the safe harbor created by those sections. This press release also contains
&#147;forward-looking information&#148; within the meaning of applicable Canadian securities laws. We refer to such forward-looking statements and forward-looking information collectively as &#147;forward-looking statements&#148;. Forward-looking
statements in this press release include statements regarding the registered direct offering and the anticipated use of proceeds therefrom, and may also relate to the Company&#146;s future outlook or financial position and anticipated events or
results and may include statements regarding the financial position, business strategy, budgets, expansion plans, litigation, projected production, projected costs, capital expenditures, financial results, taxes, plans and objectives of or involving
the Company. Particularly, statements regarding future results, performance, achievements, prospects or opportunities for the Company, the greenhouse vegetable or produce industry or the cannabis industry are forward-looking statements. In some
cases, forward-looking information can be identified by such terms as &#147;outlook&#148;, &#147;may&#148;, &#147;can&#148;, &#147;might&#148;, &#147;will&#148;, &#147;could&#148;, &#147;should&#148;, &#147;would&#148;, &#147;occur&#148;,
&#147;expect&#148;, &#147;plan&#148;, &#147;anticipate&#148;, &#147;believe&#148;, &#147;intend&#148;, &#147;try&#148;, &#147;estimate&#148;, &#147;predict&#148;, &#147;potential&#148;, &#147;continue&#148;, &#147;likely&#148;, &#147;schedule&#148;,
&#147;objectives&#148;, or the negative or grammatical variation thereof or other similar expressions concerning matters that are not historical facts. The forward-looking </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
statements in this press release are subject to risks that may include, but are not limited to: our limited operating history in the cannabis and cannabinoids industry, including that of Pure
Sunfarms Corp. (&#147;Pure Sunfarms&#148;), Rose LifeScience Inc. (&#147;Rose&#148; or &#147;Rose LifeScience&#148;) and Balanced Health Botanicals, LLC (&#147;Balanced Health&#148; or &#147;Balanced Health Botanicals&#148;); the legal status of the
cannabis business of Pure Sunfarms and Rose and the hemp business of Balanced Health; risks relating to the integration of Balanced Health and Rose into our consolidated business; risks relating to obtaining additional financing, including our
dependence upon credit facilities; potential difficulties in achieving and/or maintaining profitability; variability of product pricing; risks inherent in the cannabis, hemp, CBD, cannabinoids, and agricultural businesses; market position; ability
to leverage current business relationships for future business involving hemp and cannabinoids; the ability of Pure Sunfarms and Rose to cultivate and distribute cannabis in Canada; existing and new governmental regulations, including risks related
to regulatory compliance and regarding obtaining and maintaining licenses; legal and operational risks relating to expected conversion of our greenhouses to cannabis production in Canada and in the United States; risks related to rules and
regulations at the US federal (Food and Drug Administration and United States Department of Agriculture), state and municipal rules and regulations with respect to produce and hemp, cannabidiol-based products commercialization; retail consolidation,
technological advances and other forms of competition; transportation disruptions; product liability and other potential litigation; retention of key executives; labor issues; uninsured and underinsured losses; vulnerability to rising energy costs;
inflationary effects on costs of cultivation and transportation; recessionary effects on demand of our products; environmental, health and safety risks, foreign exchange exposure, risks associated with cross-border trade; difficulties in managing
our growth; restrictive covenants under our credit facilities; natural catastrophes; the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic; and tax risks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has based these forward-looking statements on factors and assumptions about future events and financial trends that it believes may affect its
financial condition, results of operations, business strategy and financial needs. Although the forward-looking statements contained in this press release are based upon assumptions that management believes are reasonable based on information
currently available to management, there can be no assurance that actual results will be consistent with these forward-looking statements. Forward-looking statements necessarily involve known and unknown risks and uncertainties, many of which are
beyond the Company&#146;s control, which may cause the Company&#146;s or the industry&#146;s actual results, performance, achievements, prospects and opportunities in future periods to differ materially from those expressed or implied by such
forward-looking statements. These risks and uncertainties include, among other things, the factors contained in the Company&#146;s filings with securities regulators, including this press release. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When relying on forward-looking statements to make decisions, the Company cautions readers not to place undue reliance on these statements, as forward-looking
statements involve significant risks and uncertainties and should not be read as guarantees of future results, performance, achievements, prospects and opportunities. The forward-looking statements made in this press release relate only to events or
information as of the date on which the statements are made in this press release. Except as required by law, the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information,
future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Contact:
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stephen Ruffini </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Executive Vice President&nbsp;&amp;
Chief Financial Officer </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(407) 936.1190, Ext. 340 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>vff-20230126.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: 71.0.4 -->
<!-- Creation date: 1/30/2023 10:55:20 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:vff="http://villagefarms.com/20230126"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:us-types="http://fasb.org/us-types/2022"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://villagefarms.com/20230126"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
    <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vff-20230126_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vff-20230126_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://villagefarms.com//20230126/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>vff-20230126_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: 71.0.4 -->
<!-- Creation date: 1/30/2023 10:55:20 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Securities Act File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCountry_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Country</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCountry_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Country</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>vff-20230126_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: 71.0.4 -->
<!-- Creation date: 1/30/2023 10:55:20 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://villagefarms.com//20230126/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="vff-20230126.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://villagefarms.com//20230126/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="20.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="21.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="26.031" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="26.131" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCountry" order="26.231" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="26.331" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="31.011" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g369529g23d36.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g369529g23d36.jpg
M_]C_X  02D9)1@ ! 0$ ;P!O  #_X1#R17AI9@  34T *@    @ ! $[  (
M   -   (2H=I  0    !   (6)R=  $    :   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $9A=7-T;R!0
M875T80    60 P "    %   $*:0!  "    %   $+J2D0 "     S8U  "2
MD@ "     S8U  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M!RVUD*_^A$?C7K98!26. .?I7F.I!O''Q/L[>W7?I6A'S)9CRDDF0=JGH3D
M?@:G#>[/FZ696,7/3Y>K9Z:&^45XY;S_ &?]HF_D\N27:I^6)=S?ZE>U>R #
M%>0:<<?M'7O3!5L?]^5_PJ\-M/T9.,O[G^)'=:UXRM]$TV2]N-,U(Q1_>(@Q
MCZDG@5R_A;2O^$S\4)XWO#"(5&RTMHV+-&5.,N<#D$DX]Z]&N[2"^LY;:YC$
MD4RE'1NC CD5Y%X=OG^&OCZ;PY?7#R:9>E7AD8X"%CPQSVX*GZ9HHZPER?%;
M\"<1=5(NH_=O^)[+C(KSKXF^"I=5@CUS1U9-7LR#^[.&D4=,?[0ZCUZ5Z(&S
MTY^E#XVUSTJCI34EN==:G&K!Q9YUHWC6X\6^&8-/TV7[-KLH\J=RN?LZC[TV
M.G/8>I]J[K3-/@TK3X+.V0)%"@51Z^_U/4UY9\)@/^$Z\3 #'SMCV_>-7L&:
MUQ,5"7+';<QPDG4AS2]#D_'G@J'QEI<4/FB"ZMVW12E<@9ZJ1Z' _*N*MV^)
MOA&98W@_MJRC P!^\X'& 0-XX]C^->A'7HK?Q=)HUU,J-+"D]ON( 89*LON1
MMS^/M6[@$41K2IQY)*Z%*A&K+G@[,\^\/_%C3-6U!=/O[6;2[UFV!93E"W]W
M/!!SZBO0Q]T?2O)?C!I5M<7&C_88@-8N9_+3RN'=<=3CG@XY[9->J6R/%:PI
M(V]U159CW(')HK1ARQG#2_0>'G4YI4YZVZD]%%%<QVB50U+2H=4M3;W#S*C
MJ1%*T>X'L2N*CUO7;'P[ICWVHR&*V1@I8*6Y)P. *YG_ (6_X._Z"3_^ \G^
M%:0IS>L3&I4IKW9FGHW@31?#\[2Z7%<6S/C>$N'P^.F03@]_SKI1Q7#_ /"X
M/!O_ $$I/_ >3_"E_P"%P>#?^@E)_P" \G^%7*E6EJTS.-6A!6BTCMSTKFKO
MP'HEUJQU-(9;2^)R9[65HF8^^#@_E6;_ ,+@\&_]!*3_ ,!Y/\*/^%P>#?\
MH)2?^ \G^%.-*K'9,<JM"6[1L3^$K2]A\F^N[^[@Z&*6X(1QZ,%QN'L:U[*R
MM]/M8[:TA2&")=J1H,!17'_\+@\&_P#02D_\!Y/\*7_A<'@W_H)2?^ \G^%)
MT:K5FF*-6A'9H[.>+S860LR@]T.TC\:Y@?#GP^-6_M,170OMYD,XNI-V[U^]
M5/\ X7!X-_Z"4G_@/)_A2?\ "X/!O_02?_P'D_PHC3K15DF$JE"3NVF=I%$(
M8EC#.P QN8Y)_&N<U/X?>'M9O3=ZC:274^T*'DN)#@>@&[CK6?\ \+@\'?\
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/*,444#"BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140518824128768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jan. 26, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan. 26,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">VILLAGE FARMS INTERNATIONAL, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">A6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">001-38783<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1007671<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4700-80th Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Delta<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">BC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">V4K&#160;3N3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">604<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">940-6012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Shares, without par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VFF<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001584549<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>d369529d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="vff-20230126.xsd" xlink:type="simple"/>
    <context id="duration_2023-01-26_to_2023-01-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001584549</identifier>
        </entity>
        <period>
            <startDate>2023-01-26</startDate>
            <endDate>2023-01-26</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="duration_2023-01-26_to_2023-01-26"
      id="Hidden_dei_AmendmentFlag_duration_2023-01-26_to_2023-01-26">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2023-01-26_to_2023-01-26"
      id="Hidden_dei_EntityCentralIndexKey_duration_2023-01-26_to_2023-01-26">0001584549</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2023-01-26_to_2023-01-26">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2023-01-26_to_2023-01-26">2023-01-26</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2023-01-26_to_2023-01-26">VILLAGE FARMS INTERNATIONAL, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2023-01-26_to_2023-01-26">A6</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2023-01-26_to_2023-01-26">001-38783</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2023-01-26_to_2023-01-26">98-1007671</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2023-01-26_to_2023-01-26">4700-80th Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2023-01-26_to_2023-01-26">Delta</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2023-01-26_to_2023-01-26">BC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressCountry contextRef="duration_2023-01-26_to_2023-01-26">CA</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="duration_2023-01-26_to_2023-01-26">V4K&#160;3N3</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2023-01-26_to_2023-01-26">604</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2023-01-26_to_2023-01-26">940-6012</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2023-01-26_to_2023-01-26">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2023-01-26_to_2023-01-26">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2023-01-26_to_2023-01-26">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2023-01-26_to_2023-01-26">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2023-01-26_to_2023-01-26">Common Shares, without par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2023-01-26_to_2023-01-26">VFF</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2023-01-26_to_2023-01-26">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2023-01-26_to_2023-01-26">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>14
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MP %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @ 3XD^5I>*NQS     $P(
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MB^$_7G\!4$L! A0#%     @ 3XD^5@=!36*!    L0   !
M ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !/B3Y6LA#Z7>T
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M<W1Y;&5S+GAM;%!+ 0(4 Q0    ( $^)/E:7BKL<P    !,"   +
M      "  8P/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( $^)/E8<.&7J/P$
M #P"   /              "  740  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M    " !/B3Y6)!Z;HJT   #X 0  &@              @ 'A$0  >&PO7W)E
M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !/B3Y699!YDAD!  #/
M P  $P              @ '&$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
1    "0 ) #X"   0%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d369529d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://villagefarms.com//20230126/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d369529d8k.htm">d369529d8k.htm</File>
    <File>d369529dex101.htm</File>
    <File>d369529dex102.htm</File>
    <File>d369529dex11.htm</File>
    <File>d369529dex41.htm</File>
    <File>d369529dex51.htm</File>
    <File>d369529dex991.htm</File>
    <File>vff-20230126.xsd</File>
    <File>vff-20230126_lab.xml</File>
    <File>vff-20230126_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>19
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d369529d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 23
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d369529d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "vff-20230126_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "vff-20230126_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "vff-20230126.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "vff",
   "nsuri": "http://villagefarms.com/20230126",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d369529d8k.htm",
      "contextRef": "duration_2023-01-26_to_2023-01-26",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://villagefarms.com//20230126/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d369529d8k.htm",
      "contextRef": "duration_2023-01-26_to_2023-01-26",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://villagefarms.com//20230126/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://villagefarms.com//20230126/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://villagefarms.com//20230126/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://villagefarms.com//20230126/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://villagefarms.com//20230126/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://villagefarms.com//20230126/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://villagefarms.com//20230126/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://villagefarms.com//20230126/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://villagefarms.com//20230126/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://villagefarms.com//20230126/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://villagefarms.com//20230126/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Securities Act File Number",
        "terseLabel": "Securities Act File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://villagefarms.com//20230126/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://villagefarms.com//20230126/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://villagefarms.com//20230126/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://villagefarms.com//20230126/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://villagefarms.com//20230126/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://villagefarms.com//20230126/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://villagefarms.com//20230126/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://villagefarms.com//20230126/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://villagefarms.com//20230126/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://villagefarms.com//20230126/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://villagefarms.com//20230126/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://villagefarms.com//20230126/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>20
<FILENAME>0001193125-23-019198-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-23-019198-xbrl.zip
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MM:H&S%;5)GT(6*1_>?E<LM[X$<L L:Y^I3<?611SE_J&MAK?10/-++7-9[$
M+WQB=CKX8>".[)"0/K!2+V+T*U9XN<=:]%& <&Q,-$>Q+;<LR<@1R0E22XD0
MF<$$Q $ S(;$LVJ[UFI=!:Z(P$<J\]2-P7&U11+$T:0MO&<Y0:P*MYCW0*,P
M$H^NGA0=X&T04W"T2^/I#67 ROOL\!>AX=99AR;R)?<9W.N!57IZ@= IU8^/
MCA?$"89>WR_9[NGXRE377$6G+6G8/"Z!73HZ/'(V(.)+J/KQCC1].V>_D^Q[
M3]D&3%1N(3^(R,^0'DB/JS3F29&(\P+ 0?"1LV/[VJ.^B4J\)8_:8CCD4GX+
M+$&31VY$^;^5%5>=+KD8AKZ8,/;FS,A;T3Q;M+V#GQ@Q;I_4[R2A6.,/SCTO
M8E*:7]<0TSM/]@6-HVJU=%R-!Z0;1XS%WUY6M1D1VO#G;70O1L&32?"1^3&=
MQ;NXO#Z26U>Y@=OH#F(ZKK;CGQDA2IP/(T1<#\/#G[#L) >D+7SP]GP.T WA
M-%'LL^$S@:N%KDT#ZLW!]!RAV8VY,5AC&GX7 6-X2'UR,69N$O-'1F[[H/Q,
MKJ@O?ELJ?B= +OS_\'";+.3LU\8OVI'4;]:5U]Z 57_Q$!#RV#? C+VEW$#S
M<@X1[U;T/ZPV9LF^_XR=FVL!COUN(()M<ZAFHUHZK#JUS;9PWD DIJ7#?_YP
M7'..3B0$/#X+$6<2**2+!+3:3[!T0R@P9IT(.>ME:#>P8Y,2Y .Z"!@I^PF7
M5.LQ0-TG>OL 8CET&,2GTI;EEY<"U1[!>RUP$5]KS[<-X,8&S/VJ-GIH",XW
MC#@F=STQ)CWFBQ%R#6^J!K2UBJLV1Y4FD3[W44"Y!&F-6> !UV,!C!\F$'($
M3"32GQ )^BK[$[6">4#T@%XZ.#4;4)EB<@+S@$0%$WNO+WP $I_#P(%COB-;
M2V7I<.ORZ:[*H\ZT9Z55S11*YPNR,P7;S>H0A46UR\:/)PMSHF5&]C<(NX!C
MF$$F@4D4Y+.CIYX0?H\"MV*0+21R\ZC1.)FWPVO2PYETCN3929[M*V=ZF IG
MAAJ ?I8<),QLX782D)!&[<"(Y\RF*>Z5[CE'I'W9(;5ZM0P#-TBYWH7V:4+;
M!1/L L&#A\]@O\"(^?^U$CLE!4RM:3$OKFM-N=.@)8R3M#6?2G:N!\#*]=K9
M:HUJ6<^XGPFUWE5@ERIP%S&TV=@EJ[J;T.E&D.X]/4S^;E1AK5P"S4INAFA6
MWM=9^PW4QRO5]GK[NU4@/>>["KV2"EU)F;#H79'>5)'JK-38<W>K2&;.S15I
MMQ49\-'3^%"G-RR"!"E<VA>(:F]S'D!W>8KSWB'R77:(;+%MO$&E8@FNBRIR
M;[AE=8\GWE#X+Z@[(&V?2ODZ.XG;4O!M]QOO(XHZ^^8[C=W)$&[MR5?:]OU[
M,NO&-$PJT;8.[<U9)P+RVX #1)W4-\VXR&^T_VUI=4"[VXE3ZREK\N1] XP*
M@2K= 8V8+)(1CP<BB4E((_)(_63NT.D;M3DLP]_8!*V23]]$N[S\QO&S_+4:
MM$W;]7S'(DQF-WOO(>ZZH=*C?Y)N+-ROY#.-OK*87%^W%Y+FU0+)J\##X)J1
MWH2XJI0/,WXEHP%3O5DS]7,N"43'$*#CH@_D(1*C>( Q>H@U=2J)Q_H\T(W:
MNJI9/2#SYT"FQS_J9 \Y?'2B*IMV,%<MWB&V>.-&T(:!?JU72NM-FYT]63^I
MA0Z#_KGY,V"67W8'-B/L:J.G<':QF =:78S2K-X?MS-\4A.T]?.OEJ"^(+5
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M.P*Z!;((@P_*!S_:)6<B4?-I/EI=2BOK^\%0)6!7A\C)=;:/ PN&P?2\Z6Q
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MOKGW\/'?__'X[X>YFKH<">%7HFF*/0,[E8+5DG+!F$)$U^!)P/^.U&W5I<<
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ME)/9[LRPR,(5(N9ONO+>.W=DU&A]0ZEM056&6'##[26T%(Y!FEQ4X@9 18X
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M"_]89INT?UV2'2K'>&-0N#Y\Y6<(;)0U9Q*/4WY;<;5'KM#)=!-F <^(!+R
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MJIK?-HW20M<( P^]%S09'2H2:I@9-0XG9EETPBQ2KAJOKY,3 U-TJ]FHH*I
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MG^J%0>6'T*="DJ.%=!R&V?WXHM RZF?HZ;F4^S(<IJ,8R(FW^!SN>8H4M(Y
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M[(>A33"Y$>B(.-&B+H@SH7<G'%D9&T:I-6T 85Z7L&<X]>:8'*EV!S%Z=*[
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MNT N,*2 A[42M)$4W[7F4M&+2H2^N&*P953LC4E#TZ*3"<\C[*""I;6"?+4
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MGCMZ:%&L8&[Q@;87'4ZRH8,<P(C?M5@AP5+/'.PDMH>!!1^UA+RNOCT#GRE
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MB@,M40D;210HRH[^_>V\[<XN*<LOD=(#4A2M+5/D<G=V=EZ>>6;BK656:?N
MVXS.+UD"VW%3% '1,G@ZP%59 6?( Q>LEN@L^3^DB:+<[/UYHOC]_BHD3QM'
MD[XDAM2FE'G/?XVN$)KG((,!&,^+)[+;B[$TB:UE\).KF>;ZE0D!U(3X&?2!
MN)RJ-1Z()7Q=^)I<4;:K1&_46KX.V>>G4U"(;Z1T7MW&;T;A0U')[G*=(_QK
M4&D$3R(;2A)>V)0,$J8EUN+]F6.S$. Q!PM#M<UA6YEJM/.IGV<&J1T41FO
MW#>9Q44%!XJ:1"KA*AN^GI%Z'50V'.VS; )2[TEKJ%8;F3B@F#8DGLM&/C5
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M-%.NI1[[/E\3<8^J3GK/[=4U<'.%- IT1L["=AZ6C86D/*&7J:IO70 %,64
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M063231L1%LA.V>G=HVUX[FW#X%]H&@97FR%;&:2AC%"U=IIDB,M)+%"]O%R
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M].;\\EU0LQH'FETYBUIOA4NX%CY%_(3[:\<RS0T70(S !MORF'V%>T56/_W
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M N4][))C#G<[FZE2AZ.F@NI=<^^7]:56;R<(2K]D0*?PG)ZN,1\+EH\:*KF
MINIQ1,_-]9DSI?)JV'E3GAJKX3?I!^1];QQ\\T?QPO["S4K39]L-B4 -H_-]
M)N[ K"0KHRBY): N,2QX06[U%#C*GV9?<":2NVN\(9L)H8*LW2:S]^^C:Z5/
MN5!WC*1,*86-=IRP H>:\]'=2A>E.QKRLV2ED#F]\@Z+6FLE'5%!8XD9F/)P
M<C6%L%V(RS:WIM6%2?&6<Q.?ZR[]I0&?A^]ME4(4[HB6:%(KI2NL;OKZZOVW
M3AVU='67;J_,GE%%$% 3IE35^]VKW7KGE\^L!S5-AZ8<CDI6-G:0L]+3\$7,
M]L/XYDF)%"AXE/LS/GM]!R<MGNQ-'KW@#(6[Q2/&YF\*&S,((-&T9+5D,*ZR
MI<ESLQ%37?E^2\FL@@%!MXL=J-O*QC.2PK;SY#;FBRD(GG!%?=HN=+^;:!TW
MBU:WTR1;TR*#62CG46MT#03+R9(8E1L3=++IK.Z^OM UB?_9<A6!D[U@92T+
MR\P4#SC[7:RI#3,X;%9-=/HVZ&OPBP8/3TV+I>_B080J#H8SL3VF&8-8=,S)
MC/.@M#SJ=FM.!K]68290U@ T2:*BZ:X)MZRC1*=TE/G$'X6O6M5*8%>?GP\]
M2C8:?VQ>_&MW!MLW''M&8EII.3%QR<J6>TKNI9 IH4APKCFP]_X<*F$,;C8)
M.QLY[FU3Z,VJ9%4YJ!QXH\G.1C 31@(_%0F>7X=GW6J"7".U+<L]292[X8Y@
MQ0W!'-=S2,#='#*^N_2,(_&FPT6<B=<?Y>(&SA[(T2K$-US#B>Q'NLPP*>^R
M$3D(D\V^%;/2JNV($="Y^2 OW]T4R0E7/+U89"NID''[H6QZ<T#?G1@TE]1(
MU*-C\]>2Y2XOVG <J69>L#"R@+!4-E5J^=)2FXH+W=KG(\J7&(3&"0@E)^-#
M2J5*]GX/IGR .6O'[C B)E5F>> [XOCP+0HU=NM@^RS=SR$K3M*R3%A> 6)B
MC?=F@7[,DE7.R4<ZPC)SV8=% L Q1CL#2H"G7Z84/=-A9^D9P3ZB=@T##R!'
MQZJW%WQAN 1/.M 6R7U1>@9+R@RU@K)H0PR?Y)PCDW;8C6=PFDF180<4#9JL
M7&VZ9M%>.W+:^,<BGC* IIL1Y!0$4]*3M'*J &1&VN\XVX\%<*HS\Z$%W]!;
M7G;Q(VPTF]DZ?YD]P@HB+5NVRA4: ?V_.IDW*?A5J7P/R;PWK5:4<AA4VJ>V
MG4W8P>%'&(@&]R9]X=%8LN[EE4IA/18]-5VB4JT;ESDO 49U_-0+P5/URJ=Z
M^BRK7F'9?/5:;6=W;\R&I"O^ L,R? ^.G9(?A:"Q4L1Z%6012_60 ^9X,.=:
MS*#.*NGLC<HXAJP;29XM:3PJFF+>$O6)IFIM1LKYJDRN#>2P=5^P<AGU2A5X
MY+O3.6;C"6HG:OWU<R'GPJYPM$*HCKNJ[Z(__,#UOON!J(R0+JF*)IUR:+ ,
MEZK*$>\WR?YDSV?N3L\_#"Y'P]&I.NM_WYA9=^5X]DC$B9[+ DE.&:/\Z13L
MLK_*@1%>>(<(18WX"R[IAR3]6+T[!-Q+J;0^_R;G]3GOA3=V@0ZF)BJ[<FG4
MC26C\$CB&\):1FJ8 >:;@CB!_\4]FT$S\,9$GL]XGRM=.[)*7#I/VOW)-'.[
MFAN1KK&4E"0!R/+X4G!\7VX/3>2 4GFJBK>4L>CYCM><\BNP2_!L3;<&K3$K
MMZ)+4^5 3UL7">E1T#A#M\GRB95J#0W7ST?S,I]3[W_I1, C!%-X_TR!6Y#;
MZL19;Q&;)"V??2.>_I@<//8)2UN=>[H7B%LLO57^CEENQ)<474,_3ZC\DA_C
MZS YG+ YN."YRZX&&1/+C;%X6A54!<R424L4!=C&F5_\D&>IH!%$-EA#R+ D
MSM20PG-8>O+W *: 0)(I=PLC$S(IK.!Y6SXYA"/^5>OX5:= *"N<^:PW'T[&
MKA#Y?&+XE$)Z(V;0>8.LL'E+M_AD[:2.$NPP[DJ\ O#IQFI%AI;TVDOG#B,C
MN6L6&>K^]-#W"[!T2"0F:3<Z\BXX9\Z-<>XB%-O245BO,TH?/TN2QTGN!F:Z
MM8J!EV]/#L0NI)_XQMQ5.D=RO?9&.:2AB91N.' $OI6NGJ#;'Z_C<'/Q4]V.
M%+[KQU&IX:7B"MRFN/L<7F[F&UW_Y-#C>NM%14'O-08(FD^3-QXHJ<X1)%BD
M:=,CG_!0BI@??QS=Y:^PIX7=B3MMW7HA0'#[07R#<7S96^LO!&#'DR99<"MW
MZ]KO]^+;)T'/X7AX.>AV_/?F/'XWO#H>G)WU1X/S]U>-F,8L(9"V1KZ?@4!%
M< L@[II4P[>KA4"^YKU%^-'F@C/*W#48Z$=+0+,Q8M;;2"RZDB27<WP_ &/W
M4MHVA0TO\R@/&CG0!%S%@A/RJ(C#]@91(O%7/69H]689WWLBX:5KV9<5R @L
M8M[O54K[[:NM''GY3$OO%F '4HXW/4C?EJ\\^@0QXCFN,4J!DG(#>(P"(.M2
M^H$<G"\AHC\HU7K'<.7:]2V!8J_._S)H;#%X8:=Q)=^P61+?1"Y;;SEO(N/$
MW;8OL=\M'?:F(UQT$X))4="S6C\%!7R<_?)W)H?!#IT]0/+'QE.,CZ97M,N]
M,L5;VIG7N',:/9P]S+D%.+[$0@$ARAMX TO90S?'3EKT#_T5^35BM5/F&&-V
M.O8%LY2K#M9")^/RZ^J-3.CMX07./I$6NJ7 ,N=ZFH';BJ3L&B1&M=I=S>B4
M$"@[WC5B1 W+P:3[G+N9X 569MRN"S6"3M<@KO#XUMTB E).O4ER)W]M&IMY
M*7A8>@3:^V:>A!M\^22LVQI,07LIAT1\J&[QRF,\" @^FD[>>Z]_KW'NTZ";
M;#P\=O=!]24/(ZD-0D3^' GB@"*6#JW,Y=P1K9D@R9&$P*)VK5S]> A9XV['
M69O*,0&!.)QP*(E-E3Z1-VI^SRBRV-%!=[OO90^DJ^=9Y$[AUS:$',^"%@8T
MP)%'BV4Z2":OLI4 A\;K>EP0XGN#O]E_MJ=6N\M=M>,CKF.; PS#E,Q#_CH0
MGZ*<:=#,G4FPF=A\RBM_#[IY[V"C7[@]6O5,RX$-UUQ772>6)73N&F\]';J=
M*B%420>0OAHEI@$EP%VFL^H493M.2(ZEECN:D!+2'TP]"C;\7BP^;I0L8OI6
M!FWI"I[4TN7<!-,I?;8S\Q?E)+&TN=?O>F#S0G<Q),L*[6V@&)C*<1DT.7XF
M-)]3Q<J_Y;QB1=N\7E3N!&_A%C/I?G%G>?TD7A1\!;!S-#I_/^+&MBW7S6W_
MQC#^-B^T2"VW7&^></87_=>KTFA#MO3XI@ECP""/DY>)G+C6>EY]=TF5.ZKP
MNZI%YOKD,!RY-9/,YCYUQ[?M4K$BM^ZH.&(]?R%8&:G$YC9;Z96[CN='D%$0
M7O[:,MK.E+Y))><VM]O8!31W[U#J7]GYWP?#0\9^B%W]M?8V8\^'!50N(L72
MM$HZB-D*-8ET_''WX/'P\'_^2LC\&DV\P.ON?5:]U*KR</4T2>5"GDS*_F@_
MBC3\2L>U_X88%#6P(86<QDB:NQ$E2I261DK7-!RCJ5FA8%\HA35*;!#BP2';
M7QR%"%W]7E:4B7'_Z&R@,+*]NN@?#T>GWSW8>T"_7_1/3MSOPL[GR,VC\\N3
MP25]+*OB3QZ!")SU+ZX&^^Z'K72O,PF9S&(ZOCR4'T[<Q"__#@;S\?BD_,,'
MV0IOMA0X]V#U_6^?NL_AG\M@)K>%0-PMQ1O[^B8!;/P+MU!;'# &:'F.I!VA
MLAQ^P- *8D60I#7(3]8KUU1=3S!P,.[;P?#T[1AV^4UUV+91[F97CN25%1P=
MNB\S/3L;]L%UJ=.S\Z/^F;KH7XY'@\LK_M[A7[G;"D\;J?#TOJF O#T\6N^'
M*ZM32!8@*O/HZ'P\/G\'>_Q$MX7/U-_VZ+]233>'(A&JZEG[,(^SQX 38/F9
M&N^JMW8!YB#[783C< M9MNS6/3&"6''_S[&5,1[>V5?O=*P7!+VD"?#/I M?
MAU( ?_L!JF= OX_H]X^XFSL$+"^^W0-YFED\Z-2'B*@PZNDK0"1OH@3EZDZ_
MZ[M2 ^UV*!(%E/?TZ1W/V\_SV%L$;PY^P91/?GFW'L;"^W2<@J;[3RW?T[W8
MA0"3,-4?T'MO8!*\0K\_&I]?JC?#\;]/!Y?]LY/*EX"?_^6Z[\=U7V&H]T\#
MD=T?T>"QS_YC[T&<]96),0.YX;,IM'MK-'7S#ZG"21'=$43@\-R?24?^<NGW
MZM*?/-E3 _S2O1??YMB EAJ3WY\G_Z%TX2U)KZ_GP^_%:5>=,V;$*,]QR)FQ
M.TSK;N3U?,=RM93%R??LKXS=KQ,D:IB3$UM][HW&?L3JM\O.;0H*Y1HPZ2JY
M_8W$[F_(J/W_29\]>?8;!WCYZG?)OVUDJEX0W/TP! *?#M2;_N6[*S5$&1_1
MK0+]LQ[\>KQ[QX#W^9\9\ :AQ2\#O[E98:?&\:ZZQ*Z_V/X1(0*!X-\VQ.]-
M"!*67[<%>I4Q]&\88."/)7_ .O"%_UY$M/;'U];,@V^P/N>CK$W._HZKMYO
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M--<Y;]SC9UF2:?(/DLKEE63ZQ[*JY\!:Q <T\SAJ8WIYCS.YK>C\,JWZ/?U
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M)PC'8PH.WC"5-G:DMF#WI="4*'/O(:@KCA?LP60NT$@^3SYP]!F]288O2.C
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MA0*:P(+%-5EA& 2J3.IGUSP1'5_#D:DNP9BU;.55E%.3MB&[YYW=%HRG&;8
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M\P&^#ER(HO74=5PRQTTYUQ036";OF@ZX59LUH5R&H/WS+H40S,\ZW^SZXEZ
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M14)M\J-]\L>*LHI-^IX%7Y%3"+@-E6-W; /OQ\X-U9ITMR%;;*5NO5J0KX@
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MEY>3].>T.4(LY-[Q +GE+EV7>+8EBOH]N8L)Y.R%LKZ'?%69]O@8X?"O/_M
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M',P)&PH6J<"G)T!8@N" 85!/[H$I\3F:!](CU! P0E.E"V1>.0WJC<$K(R9
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M7\&"+4!7P6H^]Z^*-J(--L!?S#&(.^^YQG6P@3]8AT'ZF?O_ %!+ P04
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MD\Z78.D_'2K.%@CW/.XFDFILO>,NL4]E+#-L03@3OW<@G'E(=1LQ?05YZ7I
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MVW'SVZ9AS1"3]2F>W[2GO;ZJ%X[]_ M02P,$%     @ 3XD^5B-A03V&!@
MDT8  !0   !V9F8M,C R,S Q,C9?;&%B+GAM;,V<:V_;-A2&OQ?H?SCSOK1
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M\S1> _!YQDS4[XQ%0]^H6Q/_/R[XTFRX35"+E:).J. '<]:/KY:/F_+3V->
M_ZX1XV0?C\&;Z;-Z=4WS<0[D&1ZS\,+I_5#UB"@_<AFZP5]T6?U>IEGA-6!M
M-F6">VLD&N(&U9I CS.!2H5Y;[(^&T78E_9B^2:*-BB(6P7X[9BFWD,Q%<[W
MCUF]A;*G@P1NM&35RCB<XM>Y]09*R6+M0-2OA@6/<\XJW@_?CVL(R%P#W'S<
M!DRS%A*<D3A$ZECW >NI-PMIE:+M0/U#T# D;,@7BQ5+[B_*LK3F!#>$;+$5
M7C#(!MX"022"DPRPG<*:XAH+SZ)<M7H[G$<\H!X-*9O=J8M'0=V@+,NFR(9
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M.61E>#$Q+FAT;5!+ 0(4 Q0    ( $^)/E:S-95" 4   '<V 0 0
M      "  5+8  !D,S8Y-3(Y9&5X-#$N:'1M4$L! A0#%     @ 3XD^5I:E
M"V0@#P  [3X  !               ( !@1@! &0S-CDU,CED97@U,2YH=&U0
M2P$"% ,4    " !/B3Y6.MD#CSH3  #%.P  $0              @ '/)P$
M9#,V.34R.61E>#DY,2YH=&U02P$"% ,4    " !/B3Y6\>H#W@@#  #Q"0
M$               @ $X.P$ =F9F+3(P,C,P,3(V+GAS9%!+ 0(4 Q0    (
M $^)/E8C84$]A@8  )-&   4              "  6X^ 0!V9F8M,C R,S Q
M,C9?;&%B+GAM;%!+ 0(4 Q0    ( $^)/E;%+(-ZN00  !<L   4
M      "  29% 0!V9F8M,C R,S Q,C9?<')E+GAM;%!+!08     "@ * '4"
(   12@$    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
